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Coeliac disease (CD) is a chronic, immune-mediated, small intestinal gluten-
sensitive enteropathy affecting approximately 1% of individuals in the Europe 
and the U.S.  The condition is exacerbated by the consumption of food containing 
wheat gluten, rye secalin and barley hordein. The keystone of CD treatment is 
strict compliance to a gluten-free diet. Designed foods for coeliac sufferers are 
mainly based on purified wheat starch that may contain traces of gluten. Hence, a 
sensitive and specific assay system is required to ensure the purity and safety of 
commercially available gluten-free foods.  Such a system is based on the use of 
monoclonal antibodies (MAbs) raised against coeliac toxic gluten peptides.  
Several peptides have been identified in rye and barley that are thought to be 
potentially immunogenic and in turn CD toxic. An ω-gliadin/ C-hordein peptide 
(QPFPQPEQPFPW) and a rye secalin-derived peptide (QPFPQPQQPIPQ) have 
been identified from the literature as potentially CD toxic. They were assessed for 
CD in vitro immunogenicity and used to raise MAbs. 
 
We wished to investigate the in vitro responses of small intestinal gluten sensitive 
T cell lines to the described peptides. We have sought to develop MAbs to these 
coeliac toxic peptides as a prelude to developing improved assays to quantify the 
gluten content of foods for individuals with CD. In parallel to this work, using 
the available MAbs previously developed by our group, we proposed to design a 
specific Cocktail ELISA assay for gluten analysis. This would potentially provide 
an assay with improved specificity and sensitivity for CD toxic gluten proteins 
and peptides. 
 
The CD immunogenicity of ω-gliadin/ C-hordein peptide and a rye secalin-
derived peptide were assessed with T cell proliferation assays. These were 
undertaken by incorporation of 3H-thymidine to measure the immune response 
of the peptides and prolamin fractions to CD gluten sensitive small intestinal T 
cell lines. Balb c mice that received a gluten-free diet were immunised with PPD 
(tuberculin protein) conjugated to the coeliac toxic peptides described above. The 
gluten content in purified wheat starch which is used to make commercially 
available gluten-free foods was quantified using a unique cocktail ELISA by 
combining two of established MAbs raised against known CD toxic peptides.  
 
We found that the ω-gliadin/ C-hordein peptide and a rye secalin-derived 
peptide triggered positive responses in most of the CD small intestinal T cell lines 
specific to peptic-tryptic (PT) digested wheat gluten (n=9), barley hordein (n=7) 
and rye secalin (n=2), confirming their coeliac immunogenicity. The murine 
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immunisations and fusions were successful. However, IgM antibodies were 
generated by the hybridomas to the gluten peptides that could not be used for 
gluten quantification. We found that we can quantify both CD toxic gliadin and 
glutenin in separate assays, simultaneously. Our method for gluten quantification 
could represent an improvement in the specificity of gluten quantification, since 
it measures CD toxic wheat proteins, including both gliadin and glutenin, rather 
than the currently accepted method of multiplying the gliadin content by two to 
yield a value for the total gluten content. However, we found that combining the 
MAbs in a single Cocktail assay yielded lower values compared to the summation 
of the individual quantified components. 
 
The ω-gliadin/ C-hordein peptide and a rye-derived peptide are immunogenic 
and were recognised by CD gluten sensitive T cell lines. Balb c mice were 
successfully immunised with these immunogenic peptides. The resultant 
hybridomas secreted IgM rather than IgG antibodies to the peptides. The former 
of which could not be used to develop immunological assays for gluten 
quantification. Characterisation of cocktail ELISAs with more than one MAb 
combination to gluten protein demonstrated lower values of gluten than the 
summation of simultaneous quantification of the individual components. We 
concluded that CD toxic gliadin and glutenin need to be measured individually 
and the value of both proteins be added together to quantify the gluten content of 
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CHAPTER ONE: GENERAL INTRODUCTION 
Coeliac disease (CD) is a chronic, auto-immune small intestinal disorder, affecting 
approximately 1% of the Western population. It is also known as Coeliac Sprue or 
gluten-sensitive enteropathy. The aberrant immune response to gluten protein 
developes in genetically predisposed individuals. The condition is exacerbated by 
the ingestion of toxic prolamins of wheat (gliadin and glutenin), barley (hordein) 
and rye (secalin). A minority of coeliac sufferers (5%) are susceptible to oat 
avenin (Lundin 2003).   
 
The disease is initially diagnosed by the presence of abnormal IgA and IgG 
serology to tissue transglutaminase (tTG) and endomysial antibody. CD duodenal 
biopsy characterises itself by the appearance of small bowel mucosa such as 
villous atrophy, crypt hyperplasia and increased number of intraepithelial 
lymphocytes (IELs). Classical gastrointestinal symptoms include diarrhoea, 
abdominal distension and vomiting. CD is also associated with other health 
implications such as osteoporosis, dermatitis herpetiformis (DH) and increased 
risk of small bowel lymphoma and carcinoma. The keystone of treatment is strict 
lifelong compliance to a gluten free diet (GFD). The clinical and gastrointestinal 
manifestations improve if wheat related cereals, including rye and barley are 
omitted from the diet, and relapse occurs if there is consumption of gluten-
containing food.  
 
An increasing number of GF wheat alternatives are commercially available to 
complement the needs of quality life for CD patients. Designed foods for 
individuals with CD are largely based on purified wheat starch which may be 
contaminated by traces of wheat gluten. This includes including both gliadin and 
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glutenin wheat proteins. Rye and barley are CD toxic. These are known to share 
similar structures including the amino acid sequences resulting in the presence of 
CD gluten toxic epitopes. A sensitive and versatile assay system is required to 
ensure the purity and safety of specialised foods for individuals with CD. It is 
therefore important to be able quantify the amount of CD toxic fractions in such 
foods including those based on other Triticaea.  
In this thesis, many aspects in relation to CD will be presented. Chapter One is 
the General Introduction. The second chapter summarises the aims of the study. 
The investigation of barley and rye peptides immunogenicity is discussed in 
Chapter Three. Chapter Four describes the development of monoclonal 
antibodies (MAbs) to barley and rye peptides. One aspect of this study pertains to 
the aim of designing an improved Cocktail Enzyme-linked immunosorbent assay 
(ELISA) for gluten analysis in purified wheat starch; this is described in Chapter 
Five. Finally, the general discussion and conclusion are presented in Chapter Six. 
 
1.1 History of CD 
The earliest description of CD was written in Greek in the 2nd Century by 
Aretaeus of Cappodocia. The term coeliac derived from the Greek word 
‘koiliakos’, which Aretaeus recorded as the malabsorptive syndrome of chronic 
diarrhoea with abdominal distension (Adam 1856). He recorded that the 
occurrence of CD in adults was associated with incomplete digestion of food. The 
disease was further described and acknowledged by a paediatrician, Samuel Gee 
in 1887. This was the first significant description of the disease in the modern 
history of CD. Gee had included children in his observation, especially those 
between one and five years old. He stated that coeliac affection was ‘a kind of 
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chronic indigestion which is met with in persons of all ages’.  He also proposed 
that the condition could be treated with the benefit of diet. Gee recognised that 
coeliac children had problem with milk intolerance and recommended the 
avoidance of highly starched foods. He also described particular success with a 
child who was fed upon a quart of the best Dutch mussels daily, and the 
condition relapsed when the season was over (Gee 1888). The daily consumption 
of mussels treated the condition most probably due to the child’s health 
improvement, by not ingesting gluten in his diet.  
In 1924, an American physician named Dr Hass introduced a low carbohydrate 
banana diet for CD patients following a case of anorexia nervosa cured by the 
same regimen (Hass 1924). A Dutch physician, Dr. Willem Karel Dicke pioneered 
the wheat-free diet during World War II when the bread supply was scarce in 
Holland. He noticed the tremendous health improvement of his patients with 
reduced bread consumption. He realised that the affected children benefited 
noticeably when they were on wheat-free diet. He suggested that the ingestion of 
wheat proteins specifically, but not carbohydrates in general, were the cause of 
CD (Dicke 1953). The diagnosis was routinely made with faecal fat estimation by 
Dicke’s laboratory colleagues who confirmed that the exclusion of wheat, barley, 
rye and oats improved the patients’ clinical conditions (Dicke 1953). 
1.2 The prevalence of CD 
The disease prevalence was rather uncommon in the 50s indicated by the 
epidemiological studies by Davidson and Fountain (1950), with only 0.0125% of 
the populations affected in England and 0.025% in Scotland.  The estimation of 
CD prevalence has been greatly improved with the better understanding of the 
disease and development of more reliable serological screening methods. The 
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majority of CD occurrence was noted in the European populations; the 
prevalence in the UK was estimated to be around 1% of the adults aged 45 to 76 
(West 2003, Bingley 2004). Larger studies that involved four different European 
countries has shown an average of 1% prevalence; where Finland is the highest 
(2%), followed by Italy (1.2%), Northern Ireland (0.9%) and Germany (0.3%), 
respectively (Mustalahti 2010). Similar magnitude has been documented in other 
Caucasian populations in USA with prevalence of 1:133 (Fasano 2003). In many 
South American countries that are inhabited by individuals of European origin, 
CD has been quite common. The prevalence of CD was in Brazil was reported to 
be 1:214 (Oliveira 2007) whereas in Argentina, CD was found to be 1 in 167 in 
2000 adults involved in a prenuptial examination (Gomez 2001). 
 
It was also found that in a random sample of 1064 adults from Christchurch, New 
Zealand of whom 96% are Caucasians, 12 were positive for endomysial IgA 
antibody and one had been previously diagnosed with CD. Abnormal histology of 
mucosal small intestinal biopsies was confirmed in all patients with positive 
serology, which contributed to an overall prevalence of 1:82 or 1.2% (Cook 2000). 
In Australia, the overall prevalence of CD was estimated to be 1:251 or 0.4% of 
the population (Hovell 2001).    
 
The disease has been well documented in Asians from India, Pakistan, and Iran 
but it is rare or nonexistent among native Africans, Japanese, and Chinese.  The 
overall prevalence of CD in India is unclear due to limited data. CD was 
previously diagnosed more frequently in children than in adults, although this 
may reflect the acceptance of ill-health by some adults or lack of awareness of 
atypical manifestations (Cummins and Roberts-Thomson 2009). The majority of 
data originate from Northern India where wheat is the staple food rather than 
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rice that is more popular among southern population. In a field study conducted 
among school children in Punjab, the Northern Western part of India revealed 
the estimated frequency of disease was 1 in 310 (0.3%) (Sood 2006). This 
prevalence is probably an underestimation and there is a need to indicate studies 
to estimate the prevalence of CD throughout India (Gupta 2009).  
 
The prevalence of CD in the Middle East is similar to that of Europe, Australia 
and New Zealand.  CD is a relatively common in Iran, Israel and Egypt where 
wheat consumption ranks among the highest in the world. The prevalence rates 
for CD in Iran, Israel, Egypt and Turkey were 0.88% (Imanzadeh 2005), 1.1% 
(Israeli 2010), 0.53% (Abu-Zekry 2008) and 0.47% (Dalgic 2011) respectively. 
These prevalence rates are almost identical to those of a variety of countries in 
Europe. There are few clinical reports of the condition published in China and 
Japan. In these countries, the majority of the population consume rice as the 
staple food. Furthermore, human leukocyte antigen (HLA)-DQ2, a molecule that 
binds and presents peptide to antigen-specific T cells is virtually absent from the 
Japanese population but is present at low frequency in the Chinese population. 
Some new CD cases in China have been derived by the high frequency of HLA-
DQ2 and HLA-DQ8 haplotypes within this population. In addition, individuals 
and common agricultural practices have resulted increased gluten consumption 
(Wu 2010). 
 
1.3 Presentation of CD 
1.3.1 Terminology and associations 
CD has a great spectrum of clinical manifestations; this varies significantly 
between childhood and adulthood presentation. The CD predisposition is thought 
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to start in early life as studies have found equivalent rates of positive serology in 
children as in adult populations (Maki 2003). There has been variability in 
terminology used to describe the presentation of CD; this leads to the difficulty 
when comparing and evaluating CD cases. A most recent manuscript has 
suggested definition and description for each CD term (Ludwigson 2013), 
although it is particularly intended for the Oslo population. The hidden or 
undiagnosed cases of CD are illustrated as Iceberg model, shown in Figure 1.3. 
 
Classical CD was described as malabsorption, involving diarrhoea, steatorrhoea, 
weight loss and growth failure (Green 2005). These were however, no signs of 
malabsorption in non-classical CD (Ludviggson 2013). The most common non-
classical manifestations of CD in children include iron deficiency anemia, short 
stature, and delayed onset of puberty. The term silent are referring to 
asymptomatic or CD without symptoms. These patients are said to have a “silent” 
form of the disease, they have positive coeliac serology but do not do not manifest 
the symptoms commonly associated with CD; they have no symptoms that 
respond to gluten withdrawal. Anemia is considered to be an atypical or silent 
presentation of CD, compared with the classic presentation with diarrhoea (Abu 
Daya 2013). Symptomatic CD is characterised by clinically evident gastro-
intestinal and/or extra-intestinal symptoms attributable to gluten intake 
(Ludviggson 2013). Latent CD patients are found to have positive serology but a 
normal bowel biopsy even if they are consuming gluten. They may have had the 
symptoms in the past or develop them later in life. 
 
The CD presentation is also linked to the typical condition that is the most 
frequently manifested among CD individuals such as malabsorptions, diarrhoea 
and weight loss.  However, there are many other common manifestations that 
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can be classified as typical CD for instances; fatigue (Siniscalchi 2005), abdominal 
pain (van der Windt 2010), or dental enamel defects (Trotta 2013, Wierink 2007).  
 














1.3.2 Paediatric  presentation of CD 
The classical syndrome of diarrhoea has been previously known to be common 
among infants following the introduction foods possibly containing gluten (Vivas 
2008, Telega 2008) but can also present in later life (Mearin 2007). Prolonged 
breastfeeding may postpone symptoms as the symptoms appear as early as the 
food introduction (Mäki 1988). Nowadays however, majority of children under 
two manifest diarrheal symptom (Rizkalla Reily 2012, McGowan 2009); whereas, 
older children and adolescent are reported to have abdominal pain, vomiting and 



















arthritis, neurological disorder or anaemia (Tanpowpong 2012). The other 
manifestations in older children are short stature, delayed puberty, unexplained 
anaemia or iron-deficiency anaemia unresponsive to treatment, dental enamel 
defects involving secondary dentition, recurrent aphthous stomatitis, raised 
serum transaminase levels and osteopaenia. DH is a skin manifestation of CD; that 
improves with a GFD (Rodrigues and Jenkins 2006).  
 
The most common symptom among paediatric CD in Scotland is abdominal pain 
(White 2013). Severe malnutrition and nutritional deficiencies, including rickets, 
may occur if the diagnosis is delayed. Behavioral changes such as irritability or 
lethargy are common. Coeliac-crisis which is rare can be also  accompanied by 
ecchymosis (bleeding skin), hypocalcamic tetany, hypoalbuminemia, and oedema 
(Mearin 2007). Low bone density is also commonly seen among children with CD 
(Kalayci 2001) at the time of diagnosis although this is not a typical symptom. 
This in fact could become a precaution in preventing osteoporosis amongst adult 
CD individuals.  
 
1.3.3 Adults presentation of CD 
Diarrhoea presentation is the mostly common among adults, accounting for 
around 49% of CD individuals (Mukherjee 2008) but significantly lesser  
compared to approximately 100% of patients in the 1960s (Murray 2003). Weight 
loss, bloating, anorexia or abdominal pain, are mainly observed symptoms 
probably due to malabsorption. However, it has been reported that at least 30% of 
patients are overweight at the time of diagnosis (Lo et al. 2003). Besides symptom 
related to the gastrointestinal, the other presentations in adults include 
osteoporosis (Meyer 2001), iron-deficiency anaemia (Rodrigo-Saez 2011) and DH, 
a ‘CD of the skin,’ with a high frequency in CD adults (Hervonen 2002).             In 
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adults, CD has been considered a pre-malignant condition, which can progress to 
lymphoma. Increased frequency for lymphoma (6%), small bowel 
adenocarcinomas, and oesophageal and oropharyngeal squamous carcinomas have 
been described. There is a form of malignancy, the enteropathy-associated T-cell 
lymphoma (EATL), with a very high association with CD; this is in general a rare 
condition with an absolute risk of only 1:1000 (cases of CD) based on the local 
prevalence of CD. Small bowel lymphoma and EATL are very rare diseases, but 
CD is the most important risk factor for these conditions. Bone density improves 
after introduction of a GFD, but in adult CD, this improvement generally does 
not reach the normal sex- and age-matched values for the control population. In 
contrast, in childhood CD with a very early treatment, gluten exclusion prevents 
bone loss and most children reach a normal bone mass. 
 
1.4 Pathogenesis 
1.4.1 Genetic susceptibility 
The genetic susceptibility of CD is influenced by the molecules in the HLA 
region. CD specific HLA-DQ2 and HLA-DQ8-molecules are expressed on antigen 
presenting cells (APCs); they present gluten peptides efficiently to T cell 
receptors of gluten sensitive T cells (Sollid 2002, Gebe 2002). Approximately 90% 
of CD patients carry the HLA-DQ2 heterodimer encoded by the DQA1*05 and 
DQB1*02 genes, carried either in cis on the DR3-DQ2 haplotype or in trans 
where the α chain is encoded on the DR5-DQ7 haplotype on one chromosome 
and the β chain on the DR7-DQ2 haplotype on the other chromosome (Qiao 
2009). There is a lesser extent of CD association is among HLA-DQ2 negative 
patients who carry DQ8 molecules encoded by DQA1*0301/DQB1*0302 (Qiao 
2009). Individuals who are homozygous for HLA-DQ2 were reported to have five 
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fold increased risk for the development of CD compared to heterozygous carriers 
(Tjon 2010). Besides genetic predisposition, CD is initiated by an inappropriate 
immune response to gluten fractions present in Triticaea (wheat, barley and rye) 
prolamins. This is generally accepted involving two systems, the adaptive and the 
innate immune response. The illustrated Figure 1.4 presents the generally 
accepted pathogenesis of CD. 
 
Figure 1.4: Pathogenesis of CD 
 
 
1. Gluten is digested to yield peptides, which are transported into the mucosa 
and enterocytes.  
2. Key glutamine residues are deamidated by tTG. 
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3. Epitope processing and presentation occurs with HLA-DQ2 by APCs. 
4. Gluten-sensitive T cells recognize CD toxic epitopes and are stimulated. 
IFNγ is secreted. 
5. LP lymphocytes proliferate and recruit additional cellular infiltrate. 
6. CD8 T cells with cytotoxic markers increase in number in small intestinal 
epithelium. 
7. Fibroblasts are activated that produce metalloproteinase to degrade the 
matrix of the small intestinal. 
8. Plasma cells are secreted to produce disease-specific coeliac antibodies, to 
tTG and endomysium. 
9. The IELs may be involved in the innate response to gluten protein. 
 
1.4.2. Adaptive immune response 
Digested gluten peptides bind to HLA-DQ2 or DQ8 molecules on dendritic APCs 
on entering the lamina propria (LP) of the small bowel (Zimmer 2010). The 
presence of gliadin fragments alone can induce maturation of dendritic cells to 
serve as APCs (Palova-Jelinkova 2005). Prior to binding, deamidation of peptides 
is assisted by tTG (section 1.4.2.2) that increases the affinity of the binding to 
HLA molecules (section 1.4.2.1). At this point, the adaptive immune response is 
triggered in response to deamidated gluten peptides. The peptides are presented 
to T helper (Th) cells. The activated gluten sensitive Th-1 cells secrete 
inflammatory mediators and stimulate other immune cells. Interferon gamma 
(INF-γ) is released in response to Th-1 mediated inflammation (Troncone et al. 
1998). The Th-1 cell activation also converts cytotoxic T lymphocytes into 
lymphokine-activated killer cells to attack enterocytes (Meresse 2004). IFN-γ also 
stimulates fibroblasts to release matrix metalloproteinase (Daum 1999) which 
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degrades the extracellular matrix, and also stimulates disease-specific plasma cells 
to produce anti-tTG antibodies which are initially released into the LP (Sollid 
1997) then to the blood stream. B cells can also mature to become IgA antibody 
producing plasma cells. 
 
1.4.2.1 Interaction between HLA molecules peptide binding grove and epitope 
The peptide-binding properties of DQ2 have been extensively studied. Peptides 
which contain negatively charged anchor residues bind at relative positions P4, 
P6 and P7 for DQ2 and P1, P4, or P9 for DQ8 (Arentz-Hansen 2000). The 
preference for negatively charged residues for the three anchor positions in the 
middle seems to be unique for DQ2 (Figure 1.4.2.1).  
 
 
Figure 1.4.2.1: The diagrammatic representation of the interaction between DQ2 
molecule peptide-binding grove and an epitope from γ-gliadin. Key anchor points 
are at positions 1, 4, 6, 7 and 9. Negative charge is preferred at positions 4, 6 and 7.   
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E represents deamidated residue with production of glutamic acid. Q and P represent 
glutamine and proline, respectively. 
 
Gluten does not contain significant numbers of negatively charged residues but 
the charges can be introduced during post-translational modification by specific 
and targeted deamidation (Qiao 2009). Glutamine (Q) can modified to a glutamic 
acid (E) residue which has more negative polarity; this is catalysed by the enzyme 
tTG (Stenberg 2008) . The modified glutamine is accommodated in different 
pockets of DQ2 for the different epitopes. Any alteration within the peptide 
binding groove can lead to reduced reactivity, suggesting that T cell receptor 
interaction is critically sensitive to amino acid structure (Ellis 2003). 
Approximately 10-15 residues are required for optimal major histocompatibility 
complex (MHC) binding and T cell stimulation. For this, a peptic-tryptic (PT) or 
chymotropic digest of gluten may contain many suitable peptides (Dewar 2004) 
and can interact with the HLA binding grove. 
 
1.4.2.2 Role of tissue transglutaminase 
tTG is a ubiquitously expressed multifunctional protein and belongs to the vast 
transglutaminase enzyme family (Caputo et al. 2009). It is a calcium dependant 
enzyme that catalyzes the cross-linking of proteins by introducing a covalent 
bond between lysine (K) and glutamine (Q) (van de Wal, Kooy 1998). Its catalytic 
activity requires millimolar concentration of Ca2+ and it is inhibited by guanine 
nucleotides. Glutamine residues can be deamidated to glutamic acid as a side-
reaction in the absence of suitable amines or at low pH (Caputo 2009). Patients 
with active CD have autoantibodies to tTG which are highly-specific and whose 
formation is dependent on ingestion of gluten (Burkhard 2004). The upregulation 
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of tTG in the damaged intestinal site will lead to the cross-linking of tTG to 
gliadin peptides or to other proteins resulting in the formation of additional 
antigenic epitope (Caputo 2009).  tTG-gliadin peptide complexes act as hapten-
carrier complexes, which could explain the typical antibody response against tTG 
in untreated CD patients (Burkhard 2004). tTG-gliadin complexes that bind to 
tTG-specific B cells, are endocytosed and processed. Gliadin-DQ2 complexes are 
then presented by the tTG specific B cells to gliadin-specific T cells (Caputo  
2009).  
 
 The presentation and recognition of gliadin complex are necessary  for the B cells 
to secrete tTG-specific antibodies (Burkhard 2004). It has been hypothesized that 
the production of anti-tTG antibodies is driven completely by intestinal gliadin-
specific T cells, since tTG-specific T-cells seem not to exist (Caputo 2009). 
Autoantibodies against tTG are pathogenomonic of CD and identified gliadin 
epitopes contain at least one glutamine residue which is an excellent substrate for 
the deamidation activity of tTG (Mowat 2003). 
 
It has been proposed that the native gluten peptide presented by HLA-DQ2 or 
HLA-DQ8 molecules to CD4+ T-cells will lead the production of IFN-γ. IFN-γ 
results the HLA-DQ molecules to be highly expressed, therefore increases the 
presentation of gluten peptide. The increasing of gluten presentation causes 
minor tissue damage locally (Tjon 2010). tTG which is mostly intra-cellularly 
retained in an inactive form is activated upon its release during tissue damage  
either by mechanical stress, inflammation, infection or during apoptosis 
(Schuppan 2000). Deamidation by tTG increases the binding affinity of gliadin 
peptides to HLA-DQ molecules on the surface of APCs (van Belzen 2004) for T 
cells recognition (Molberg 1998). tTG enzyme converts the non-charged 
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glutamine into negatively charged glutamic acid (Tjon 2010). The deamidation of 
gluten is largely dependent on the presence of proline residues flanking the 
glutamine residues; gluten has a high content of these amino acids.  
 
Motifs such as QXP, QXXF and QXPY represent the favoured target sites for 
glutamine deamidation whereas the sequence patterns, such as QP and QXXP 
inhibit the deamidation because of the presence of a proline residue (Vader 2003) 
The introduction of negative charges at positions favoured by HLA-DQ molecules 
significantly results in high affinity binding, thus increases the immunogenicity 
of deamidated peptides (Gebe 2002) and is essential for T cell stimulation (Mowat 
2003).   
 
1.4.3 Innate immune response 
The innate activation of epithelial cells could be triggered along with adaptive 
immune response. Interleukin-15 (IL-15) is a pro-inflammatory cytokine 
involved in both adaptive and innate immunity. IL-15 released by APCs, is 
signalled by LP T cell IFN-γ (Waldmann 1999). In addition, LP APCs can produce 
IL-15 in response to specific gliadin peptide such as p31-43 (Maiuri 2003). This 
peptide has demonstrated CD toxicity  in organ culture (Shidrawi 1995) and in-
vivo (Sturgess 1994). Proliferation of cytotoxic CD8+ve intraepithelial 
lymphocytes (IELs) is promoted by IL-15 (Di Sabatino 2011).  
 
IL-15 also stimulates IEL cytotoxic activity in duodenal epithelium via granzyme, 
perforin and Fas/FasL pathways (Junker 2009). The intestinal epithelial cells 
destruction could be pictured as the appearance of villous atrophy. It is not very 
clear which mechanism is predominant to the other, the adaptive or innate 
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response. The inflammatory effects are perhaps initialised by the epithelial 
activation then continuously trigger the LP response. The changes of pathological 
appearance in the mucosa of coeliac individuals have been noticed an hour after 
gluten ingestion (Maiuri 1996, Ciclitira 1984,) that could not be possibly caused 
by T cell activation. 
 
1.5 CD exacerbation 
1.5.1 Taxonomy 
In plant taxonomy, the grass family (Graminae) belongs to the plant kingdom 
subclass Monocotyledoneae or monocots. The only other grouping at the subclass 
level is that of Dicotyledoneae or dicots. Some species about which coeliac 
patients have questions are actually dicots, which have a very distant relationship 
to the grass family. Such species include buckwheat, amaranth, quinoa, and 
rapeseed. Because of their very distant relationship to the grass family including 
wheat, it is highly unlikely that these dicots contain the same type of protein 
sequence found in wheat proteins that causes problems for coeliac patients.  
 
The three harmful species (wheat, rye, and barley) are members of the grass or 
Gramineae family and are quite closely related to one another according to 
taxonomy (Figure 1.5). However, not all members of the grass family damage the 
intestines of individuals with CD. Rice and corn (maize), for example, are 
apparently harmless. Members of the grass family that are more closely related to 
these species (based on taxonomy) than to wheat are likely to be safe. Such 
grasses include sorghum, millet, teff, ragi, and Job’s tears, which appear to be 
closely related to maize. Species within the genus Triticum are almost certain to 
be harmful to individuals with CD. Grain proteins found in these species such as 
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spelt include the various types characteristic of the gluten proteins found in bread 
wheats (including the α-gliadins) that cause damage to the small intestine of 
coeliac patients. Rye (Secale cereale) and barley (Hordeum vulgare) which are 
toxic in coeliac patients belong to different genera, Secale and Hordeum, 




Figure 1.5: The taxonomic relationship of cereals (confirmed toxic cereals are shown in boldface) 
GRAMINEAE 
Bambusoideae 
Oryzeae Triticeae   Paniceae 
Chloridoideae       Panicoideae 
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Gluten proteins are unusual in their high proline and glutamine content, 
comprising 15% and 35% of residues, respectively. A common feature of 
wheat prolamins is a high content of glutamine (>30%) and proline (15%), 
whereas the CD non-toxic prolamins of rice have a lower glutamine and 
proline content (Table 1.5.2). Proline is a secondary amide and causes a kink 
in the polypeptide backbone. Peptidases are unable to cleave the adjacent 
peptide bonds and therefore the presence of proline residues often dictates the 
fragments produced by proteolysis. Glutamine contains an additional γ-
carboxamide group and can be deamidated to glutamic acid rendering a 
negative charge (Dewar 2004). 
 
Table 1.5.2:  The major prolamines that can drive the immune response in 
CD, which are rich in glutamine and proline (Schuppan 2000). 
 
Cereal  Prolamin Composition 
  Glutamine   Proline 
Wheat Gliadin  36% 17%-23% 
Barley Hordeins 36% 17%-23% 
Rye Secalins 36% 17%-23% 
Oats Avenins High  Low 
Maize Zeins Low High 
Rice Rice prolamin Low High 
 
1.5.2.1 Wheat gluten 
Gluten is a rubbery mass that consists of storage proteins that remain after 
starch is washed from wheat-flour dough. These proteins have different 
solubility in alcohol/water solutions thus, can be roughly separated into two 
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fractions, gliadins (alcohol-soluble) and glutenins (alcohol-insoluble). Gluten 
proteins can be categorized into three main groups: 1) the sulphur (S) rich 
group (MW of 50kD), 2) the sulphur (S) poor group (MW of 50kD) and 3) the 
high molecular weight glutenin (HMW) with MW around 100kD. The first 
group comprises of ω-gliadin and D-type low molecular weight glutenin 
subunits (LMW-GS). The second consist of three major families: the B-type 
LMW-GS, the γ- and α-gliadins. Finally, the third group is further divided 
into two subgroups, the S-rich and S-poor (Figure 1.5.2.1). Gluten proteins 
have a complex chemistry and are responsible for the baking properties of 
wheat such as water absorption capacity, cohesivity, viscosity, and dough 
elasticity. The α-, γ-gliadins, B- and C-LMW glutenin subunits are grouped in 





























Figure 1.5.2.1: The classification of wheat gluten proteins based on 





















The alcohol soluble gliadins are predominantly monomeric proteins of 30-78 
kDa which can be separated at low pH according to electrophoretic mobility 
in acid polyacrylamide gel electrophoresis (Shewry 1992).  The separation 
results in four groups which are α-, β-, γ- and ω-gliadins. The α-, β-, and γ-
gliadins contain intra-chain disulfide bonds which cannot be found in the ω-


















Gliadin has been mainly described as CD toxic (Mazzarella 2003, Fraser 2003, 
Ellis 2003, Anderson 2000, Arentz-Hansen 2000). In α/β gliadin molecules, 
several toxic epitopes were found such as gliadin-α2 
(QPFPQPQLPYPQPQLPY) and gliadin-α9 (QLPPFPQPQLPYPQ) whereas, in 
the γ-gliadin molecule, gliadin-γ1 (PQQPQQSFPQQQRPF) and gliadin-γ2 
(QQPFPQQPQQPFPQ) are the main toxic epitopes, which can present in 
hordeins (barley) and secalins (rye) (Vader 2003). 
 
The alcohol insoluble glutenins can be divided into groups of HMW and 
LMW. Based on their mobilities on SDS-PAGE, three groups of LMW 
glutenins have been identified: B- (42-51kDa), C- (30-40kDa) and D-LMW 
(55-70kDa) (Lindsay and Skerritt 1999). HMW glutenin subunits are about 65-
90kDa (Shewry and Halford 2002). Hydrated glutenins are responsible for 
dough strength and elasticity. Immunogenicity and toxicity in the HMW 
group have been well described (Ellis 2006, Dewar 2006, Molberg 2003, Vader 
2002, Molberg 2001, van de Wal 1999). 
 
1.5.2.2 Rye and Barley prolamins 
Rye and barley have a unique composition of cereal prolamins due to the high 
content of glutamine and proline that is similar to wheat gluten. They are 
referred as secalin (from rye) and hordein (from barley), respectively. Both 
grains contain S-rich, S-poor and HMW prolamins, but no α-type S-rich 
prolamins. Two types of γ-type S-rich prolamins are found in rye; both are 
distinct in Mr and aggregation properties. Formation of polymers stabilised by 
interchain disulphide bonds are found in Mr 75 000 γ-secalin, whereas Mr 40 
000 γ-secalin are monomers (Table 1.5.2.2). The homologous groups of S-rich 
S-poor and HMW prolamins present in rye and barley are summarised in 
Table 1.5.2.2 (Shewry 1992).  
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Table 1.5.2.2:   Classification of rye and barley prolamins (Shewry 1992) 
 
Components Rye Barley 
S-rich prolamins 
  γ-type 
 
  α-type 
  Aggregated type 
 
Mr 40 000 γ-secalin 








S-poor prolamins ω-secalins C hordein 
HMW prolamins HMW secalins D hordein 
 
Besides wheat, they are known to be toxic to individuals with CD. They 
should be excluded from GF diet. Tye-Din (2010) has recently extended the 
evidence for immunostimulatory T cell epitopes in wheat, rye and barley. 
Apart from ω-gliadin peptide found to be the most immunodominant, Tye-
Din has demonstrated other potential immunogenic peptides from barley and 
rye. His work has lead to the in-vitro immunogenic study that will be 
explained in Chapter Three.        
   
Rye and barley have also previously been shown to be homologues to CD toxic 
gliadin (Vader 2003). Vader used T cell lines and clones from 8 different 
patients with CD to test 11 amino acid peptides from a selection of epitopes 
from rye and barley similar. They found that over 63% were recognised by 
gluten specific T cells lines or clones of CD patients. The gliadin-γ-2 epitope is 
not only present in γ-gliadin but also in secalins and hordeins. The gliadin-γ-2 
homologues (present in secalins and hordeins) are reported to be equally 
recognized by gliadin-γ-2 specific T-cells. The secalin-γ-1 sequence also aligns 
at the same region of gliadin-γ-1, whereas, gliadin-α-2 and gliadin-α-9 
homologues are present found in a secalin molecule (Vader 2003).  
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The immunogenicity of barley and rye prolamins was also investigated by 
quantifying the pro-inflammatory cytokines, IFN-γ and interleukin-2 (IL-2) 
using Taqman Polymerase chain reaction (PCR) and ELISA (Bracken 2005). It 
was shown that hordeins, and secalins resulted in significant increase of 
interferon γ-mRNA in small intestinal biopsies from individuals with CD. 
 
1.5.2.3 Oat avenin 
The status of oats has been reassessed in the international GF standard (Codex 
Alimentarius Commission 2008). They remain in the category of gluten 
containing cereals but there is an additional note stated that the use of oats not 
contaminated with wheat, rye or barley in foods is covered by the standard 
which may be determined on a national level (Codex Alimentarius 
Commission, 2008). Many extensive, long-term intervention studies with 
moderate intake of oats as part of GF diet have suggested its safety. The 
clinical study outcomes on oat challenge ranging from 2.5g of pure avenins to 
as much as 50g per day oat intake showed no histological changes (Huttner 
and Arendt 2010). 
 However, it was also indicated by the author that there were two publications 
(Arentz-Hansen 2004) and (Lundin 2003) that showed oats could induce 
mucosal inflammation in small subgroup of CD patients who are sensitive to 
oats (Huttner and Arendt 2010). Avenin sensitive T cell lines were obtained 
from small intestinal biopsies of individuals with CD. Oats were reported to 
improve the nutritional value of the GF diet without any negative effects on 
nutritional status. They  therefore could help patients following a strict GFD 
(Butt 2008). It was also found that immunogenic sequences present in gliadin, 
are absent in oat avenins (Kilmartin 2003; Butt 2008).  
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Avenins contain half of the proline content found in other CD toxic prolamins 
including wheat gluten, secalins and hordeins (Huttner and Arendt 2010). In 
oats, protein classes are distributed differently with the largest group is 
dominated by globulins and only 10% representing prolamins. On the other 
hand, prolamins in wheat comprise about 80% of the total storage protein and 
10% of the rest is globulin (Huttner and Arendt 2010). As such, oats are 
considered tolerable in individuals with CD. 
The majority of oats available in Europe was reported to be contaminated with 
other CD toxic cereals. However, a study conducted with the synthetic avenin 
peptides demonstrated that the peptide epitope was not identical to the 
immunodominant gliadin peptide (PFPQPELPY). This suggests that there was 
no gliadin peptide contamination (Arentz-Hansen 2000). Many studies have 
seemingly shown that the intolerance to oats among CD patients is infrequent. 
Only a small number of patients have oat-sensitive small intestinal T-cells. 
Therefore, it is recommended that CD sufferers adhere to a strict GFD, as well 
as avoiding oats until clinical and histological remission has been achieved 
(Ellis and Ciclitira 2008). A recent study suggested that not all cultivars of 
quinoa are safe for CD patients to eat as evidenced by T cell activation 
(Zevallos 2012). However, the clinical feeding study implied that quinoa can 
be safely tolerated by individuals with CD (Zevallos 2014). 
 
1.6 Diagnosis of CD 
1.6.1 ESPGHAN guidelines for CD diagnosis 
The European Society of Paediatric Gastroenterology and Nutrition 
(ESPGHAN) first proposed a guideline for CD diagnosis in 1970 (Meeuwisse 
1970). The original statement for CD diagnosis is based on three criteria; 
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1) A minimum of three endoscopies based on structurally abnormal 
mucosa whilst still consuming gluten 
2) Clear improvement of villous structure when commencing a GFD 
3) Reappearance of mucosal damage resulting from gluten challenge. 
 
In 1990, the criteria were revised (Walker-Smith 1990) after it was found 
gluten challenge were not required in all situations. The second and third 
biopsies were eliminated. Instead, the diagnosis should be based on the first 
biopsy and histological examination showing the characteristic abnormalities, 
that is, lymphocytic infiltration, villous atrophy and crypt hyperplasia, on a 
gluten-containing diet. In children under the age of 2 a gluten re-challenge 
and small intestinal biopsy is still required for the diagnosis of CD.  
 
Based on ESPGHAN guidelines, an evidence-based approach (Husby 2012), 
three antibodies are considered as coeliac-specific. They are: 
1) Endomysial antibody (EMA)  
2) Transglutaminase 2-specific antibody (anti-TG2) 
3) Deamidated gliadin-specific antibody (anti-DGP) 
 
It has also been proposed that the histological assessment could be excluded if 
the individual show symptoms that can be referred to CD, the IgA anti-tTG 
levels is ten times higher than the upper normal limit, verified by EMA 
positivity and the individual is HLA DQ2 and/or DQ8 positive ( Husby 2012). 
 
1.6.2 Immunological markers and screening 
Immunological response to the presence of gluten results in the production of 
auto-antibodies that is one of the characteristic of CD. Serological screening is 
the first crucial step for the CD diagnosis and is useful in monitoring GFD 
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commitment. The screening of CD has been improved by reliable serological 
markers; initially with IgA and IgG AGA, later the EMA and IgA anti-tTG 
antibodies, and most recently, deamidated gliadin peptide (DGP) antibody 
(IgA anti-DGP). The commonly used serologies are summarised in Table 1.6.2 
 
Table 1.6.2: Comparison of serological tests for their sensitivity and 
specificity (modified after Leffler 2010) 
 






probability of 5% 
Negative predictive 
value (%),pretest 
probability of 5% 
IgG AGA 85 90 18 99 
IgA AGA 85 80 31 99 
EMA 95 99 83 99 
IgA  anti-tTG 98 98 72 99 
IgG  anti-tTG  70 95 42 99 
IgA  anti-DGP 88 95 44 99 
IgA  anti-DGP 80 98 68 99 
IgA/IGg  anti-
DGP 
97 95 51 99 
 
The first serological test was AGA developed in the early 1980s (Leffler 2010) 
that measured both IgG and IgA AGA. However, these antibodies were 
reported to have relatively low sensitivity and specificity that is between 80% 
to 90% (Naiyer 2009). AGAs were also reported to yield false-positives in 
patients with other causes of mucosal damage in the gastrointestinal tract. 
Much improved accuracy was reported with deamidated peptide AGA (Leeds 
et al. 2008).               
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The EMA testing was first described in CD more than 30 years ago and rapidly 
replaced AGA because of their higher specificity. AGA can be found in 
healthy individuals but EMA is unlikely to be found in non-CD patients. The 
test initially utilized monkey oesophageal tissue as substrate but was replaced 
later by human umbilical cord which was more sensitive and specific 
(McGough and Cummings 2005). The test also depended on 
immunofluorescence, and uses tTG as the target antigen (Leffler 2010). The 
sensitivity of IgA anti-EMA is generally more than 90% with a specificity of 
97-100% (Fasano 2012). Despite of its high sensititivity, IgA anti-EMA is 
costly and inapplicable to evaluate CD individuals with IgA deficiency 
(Cataldo 1998, Salmi 2006). EMA was also found to be present in active CD 
but could be disappeared due to continuous GFD.  
 
Following the recognition of tTG in the late 1990s (Dieterich 1998), IgA anti-
tTG ELISA was developed. The first generation assays utilised guinea pig liver, 
subsequently replaced by human erythrocytes and human recombinant tTG 
(Dieterich 1998). The latter was reported to yield higher specificity when used 
as coating antigen (Lewis 2006, Tonutti 2003,). The anti tTG ELISA is simpler, 
less expensive and time saving (Van Meensel 2004). Hence, the IgA anti-tTG is 
recommended as the initial evaluation of CD. The IgG anti-tTG is also 
available for use in individuals with IgA deficiency (Fasano 2012).  
 
Antibodies to DGP have been shown to be of diagnostic value (Volta 2010). 
The evaluation is based on the antibody response that has higher specificity 
for CD than antibodies to native gluten (Prince 2006). The IgA and IgG anti 
DGP assays were reported to have higher sensitivity than anti-tTG IgA and 
AGA IgA in monitoring compliance with GFD in children with CD (Monzani 




1.6.3 The histological of biopsies  
The histological assessment of duodenal biopsies is the gold standard in the 
diagnosis of CD (Rostom 2006) that is performed after positive serological 
testing. The diagnosis is usually made on the basis of an abnormal duodenal 
biopsy on gluten containing diet and subsequent histological improvement 
after GFD (Figure 1.6.3). 
 
Figure 1.6.3: Histological appearance of the stained small intestinal mucosa 




a) Appearance of villous flattening, crypt depth hyperplasia and the 
expansion of LP with chronic inflammatory cells in the small intestinal 
mucosa. There are also increased numbers of lymphocytes within the 
epithelial layer. 
b) Section of normal intestines with clear architectural presence of tall and 




The histological assessments are described in Table 1.6.3 using Marsh-
Oberhuber classification (Oberhuber 1999). The criteria observed on mucosal 
small bowel biopsy specimens include villous architecture, crypts changes and 
IEL counts/100 enterocytes (Marsh 1992, Oberhuber 1999). A Marsh I type 
comprises normal architecture of mucosa with lymphocytic filtration of the 
villous epithelial layer. Marsh II describes hyperplastic appearance with IELs 
in excess of 30 per 100 enterocytes.  The villous height/crypt dept ratio will 
often become below the normal value 3-5. The particular feature of Marsh III 
is villous atrophy, that is extended to several degrees; the mild, moderate and 
total villous atrophy. A Marsh 4 describes a rare histological finding of a flat, 
atrophic mucosa thought to be resulted from chronic inflammation.  
 
Table 1.6.3:   Marsh-Oberhuber classification of CD 
Marsh  
class 








Normal Hyperplasia >30/100  
enterocytes 
Marsh III 
  3A 
   
   
  3B 
 
 














































1.7 Complications and associations of CD 
1.7.1 Autoimmune diseases 
CD has been associated with several other conditions. Prolonged exposure to 
gluten may contribute to the development of autoimmune disease, or could be 
influenced by other factors (Sategna Guidetti 2010, Ventura 1999). CD 
presents atypically and unexpectedly in children and adolescents with type 1 
diabetes mellitus (T1DM) (Goh 2007). It is considered the most notable 
complication that is around 11% of CD sufferers (Keskin 2010). The 
compliance to GFD improves health and weight, and reduces the 
hypoglycaemic episodes in some cases (Hansen 2006). Autoimmune thyroid 
disease (ATD) is another recognised association. The prevalence of ATD is 
reported ranging from 2.3% to 7.8% in children and adolescent (Sattar 2011). 
Around 6.4% of patients were reported to have autoimmune hepatitis (AIH), 
those who showed positive serologies and histological appearance associated 
with CD (Nastasio 2013).  
 
1.7.2 Neurological manifestation  
Neurological manifestations have been reported more prominent in adult 
patients than in paediatrics. Depression is one the most common condition 
that could happen if the diagnosis is delayed and the diet is being restricted to 
GFD. Depressed CD sufferers are prone to sleep disorders (Zingone 2010) and 
in some cases it could be severe to the extent of committing suicide 
(Ludvigsson 2011). Prevalence of chronic headaches, hypotonia, learning 
disabilities or ADHD has been reported increasing (Zelnik 2004). 
Hadjivassiliou and colleagues reported the neurological disorders in the 
majority of these patients that were termed as ataxia or peripheral neuropathy 
(Hadjivassiliou 1996). Accumulation of gluten ataxia is probably due to the 
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association with HLA-DQ2 and DQ8, the presence of circulating Purkinje 
antibodies and the presence of anti-tTG antibody in the gut and brain 
(Hadjivassiliou 2008).  
 
1.7.3 Pregnancy and CD 
Infertility and poorer outcome of pregnancy have known to be a complication 
of CD (Freeman 2010, Ozgor 2010). Women are reported to suffer recurrent 
miscarriage, low birth weight infant and increased mortality children (Sher 
1994). The younger female had shown to have lower fertility, but higher 
fertility when they are older when compared to general population controls 
(Tata 2005). Affected fathers could suffer sub-fertility and indirectly linked to 
the low birth weight infant compared to offspring of an unaffected father 
(Ludvigsson 2001).  
1.7.4 Ulcerative Jejunitis 
Ulcerative jejunitis is often associated with refractory CD in adults but it has 
been recently reported to present in children. Ulcerative jejunitis is another 
cause of non-responsive CD. It is a rare disorder characterised by the 
ulceration of the jejunum and ileum. Scarring often occurs, leading to 
structure formation with alternating areas of dilated small bowel. Ulcers can 
be of varying depth and can extend through the entire thickness of the bowel 
leading to perforation (Bayless 1970). Steroids are commonly used to treat the 
ulceration and a strict GFD is essential.  
1.7.5 DH skin disorder 
DH is a gluten sensitive skin disorder (Figure 1.7.5) characterised by an 
intense itching and papulo–vesicle eruption primarily affecting the elbows, 
knees and buttocks (Moazzem Hossain 2009). On histological evaluation the 
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majority of DH patients are found to have an abnormal jejunal mucosa, 
however only 10% of patients suffer from any kind of malabsorption. 
Diagnosis is established by the demonstration of IgA autoantibodies at the 
dermo-epidermal junction, by immunofluorescence binding to these immune 
deposits. Recently, anti-tTG 3 antibodies have been shown to produce these 
deposits (Zone 2011). Patients who are advised to commence GFD usually 
show significant improvement within 6-12 months. Patients are also 
prescribed 50-100mg/ daily of Dapsone at the initial stage of manifestation and 
minimum dose required to control the rash may be reduced. 
 




CD has been associated with malignancies. The risk of malignancies has been 
reported not to be significantly after the patients comply with a GFD (Olen 
2011). Coeliac patients have an increased risk of developing cancer if diagnosis 
is delayed (Silano 2007). This is probably due to the prolonged period of 
dietary exposure to gluten (Carrao 2001). This risk is more relevant for the 
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intestine-specific cancers such as small bowel carcinoma and non Hodkin's 
lymphoma. It has been also noted that CD individuals have a higher risk of 
developing a small bowel adenocarcinoma compared to the general population 
(Green 2004, Rampertab 2003). Adenocarcinoma of the small intestine is a 
rare cancer, demonstrated to affect 13% of patients with CD. 
 
 The overall survival at 30 was 58% and was not affected by the presence of 
CD (Howdle 2003). EATL is another type of rare lymphoma associated with 
CD, affecting 0.5-1.0 per million of Western populations (Delabie 2011). The 
survival from EATL is estimated 8-10% at 5 years (Al-Toma 2007). EATL has a 
peak incidence in jejunum in the sixth decade and is associated with refractory 
gastrointestinal symptoms as well as non-gastrointestinal sites.  
 
1.8 Treatment of CD 
1.8.1 GFD 
The basis of CD treatment is lifelong adherence to a GFD that is avoiding 
products from rye and barley. In the vast majority, this leads to resolution of 
symptoms and a reduction in long-term risks of the complications associated 
with this disease. It was also reported that half of the CD patients do not 
achieve histological improvement with a GFD (Tye-Din 2010). The new 
Codex Alimentarius Standard for gluten-free food has been adopted following 
the agreement at European level. The new composition and labelling of 
foodstuffs suitable for people intolerant to gluten has been applied since 
January 2012, after being amended in 2008. The food labelled gluten-free may 
not contain wheat, rye, barley or oats, and its gluten level must not exceed 20 
mg/kg whereas foods with gluten content 21-100mg/kg should be labelled as 
low gluten food (Codex Alimentarius Commission 2008).  
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However, complying with GFD is difficult and decreases quality of life due to 
poor sensational characterisation. A strict GFD is low in dietary fibre and 
folate, niacin and vitamin B12 (Thompson 2005, Thompson 2000). Several 
problems arise in relation to compliance with a GFD. First, the harmful gluten 
may contaminate food during the preparatory and processing steps (Ellis 
2008b, Hernando 2008). Second, there is social pressure, especially in young 
patients to consume gluten (Fabiani 2000). Next, gluten-free products are not 
widely available and usually more expensive (Singh 2011). A GFD also has a 
poor palatability (Lerner 2010). Many gluten-free products are made from 
purified wheat starch (Ellis 2008b) that could contain traces amount of gluten.  
 
1.8.2 Nutrition replacement 
CD sufferers could consume naturally gluten-free cereals such as rice, millet, 
maize, sorghum and quinoa. Quinoa, contains all essential amino acids and 
high in minerals and vitamins that could be the perfect alternative to wheat. 
The consumption 50 g of quinoa over 6 weeks can be well tolerated by coeliac 
patients and did not exacerbate the condition. There was a histological 
improvement and positive trend in serological parameters, particularly a mild 
hypocholesterolemic effect (Zevallos 2014). In addition to compliance to GFD, 
patients with a low bone mineral density (BMD) should avoid smoking and 
excessive alcohol intake, and take calcium and vitamin D supplements (BSG 
Guidelines 2007).  
 
1.9 Methods for assessing the toxicity of gluten fractions and peptides 
This section describes techniques involving human tissue that have been used 
previously to study coeliac toxic gluten fractions, and some are being used 
with this current study. The current toxicity testing in is further subdivided 
into in vitro methods and in vivo methods.  
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1.9.1 In vitro 
1.9.1.1 Organ culture of small intestinal biopsy 
Browning and Trier first described a method by culturing a jejunal biopsy for 
48 hours using an in vitro organ culture system (Browning and Tier 1969). 
This was subsequently employed to investigate the changes in cultured 
biopsies from patients on normal and a GFD, and controls in the presence or 
absence of prolamins (Falchuk 1974). The test substances used were PT gliadin 
or casein and untreated α-gliadin, with culture medium as a control. The 
parameters used to assess the biopsies were refined to use mean surface-
enterocyte cell height (ECH), IEL count and villous height: crypt depth ratio 
(Howdle 1984). This technique requires only milligram quantities of peptides 
and around six biopsies are frequently obtained to conduct adequate tests. This 
method has now been used by a number of other researchers in assessing the 
toxicity of gluten fractions (Mazzarella 2003, Martucci 2003, Biagi 1999, 
Beckett 1999, Shidrawi 1995, Howdle 1984).  
 
1.9.1.2 Small intestinal T cell culture 
This assay is used to assess gluten sensitive T cells proliferation in response to 
the candidate peptides or prolamins presented by inactivated APCs. The APCs 
are the irradiated (22 Gray) peripheral blood mononuclear cells (PBMCs) from 
CD patients. T cells with phythohaemagglutinin (PHA) are used as a positive 
control. PHA is a plant lectin that triggers lymphocyte agglutination and 
proliferation. The T cells with APCs are used as the baseline for the 
stimulation indices (SI) calculation. Proliferation assays are undertaken when 
there is sufficient number of T cells. Cells are labelled for 18 hours with 
tritiated thymidine (3H) before cell count is done. SI is calculated by dividing 
the mean counts per minute (CPM) of the T cells with APC and antigen by 
the mean CPM of the T cells with APC alone. Positive SI is noted as greater 
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than 2.0 and demonstrates the CD toxic of the tested antigen (peptides and 
prolamins) This method has been used to identify the toxic epitopes in gliadin 
by many researchers (Suligoj 2013, Zevallos 2011, Dewar 2006, Ellis 2003, 
Anderson 2000, Arentz-Hansen 2000) and applied in this current study. The 
adoption of this method is explained in details in Chapter Three. 
 
1.9.1.3 Immunological tests of lymphocyte stimulation. 
Peripheral blood lymphocytes are cultured in the presence of antigen that 
could stimulate the cell proliferation. Similar to the assessment of T cells 
proliferation (Section 1.9.1.2); the lymphocytes are cultured in the presence of 
radioactively labelled thymidine. DNA synthesis in cultured lymphocytes was 
reported to increase in the presence of Frazers Fraction III (Sikora et al. 1976). 
This method was also employed using PHA and Tuberculin purified protein 
derivative (PPD) as test antigens where the concentrations can be optimised.  
Previously, this was employed as the prelude of a test for cells proliferation 
before undertaking small intestinal in vitro study. The results are also 
expressed as stimulation index by dividing the average CPM of cells incubated 
with PHA or PPD with CPM of the cells (peripheral blood lymphocytes) 
themselves. The material used in this test is rather irrelevant to current CD 
studies compared to small intestinal T cell lines generated from CD biopsies. 
 
1.9.2 In vivo  
In vivo gluten challenge remains the gold standard method for testing gluten 
fractions and candidate peptides. Before any protein or peptide can be 
addressed as CD toxic or non-CD toxic to CD patients, feeding experiments 
will be performed before biopsies are obtained. In early study, gluten 
challenge was followed by faecal fat measurement (Van de Kamer 1953), 
however morphometric analyses of small intestinal biopsies have since been 
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taken into account. Treated coeliac volunteers undergo 
oesophagostroduodenoscopy (OGDs) at the beginning and at the end of the 
procedure. A Quinton hydraulic suction biopsy capsule is placed in the 
proximal jejunum by fluoroscopic control. The test peptide is infused intra-
duodenally over an hour of time. Multiple biopsies are collected at hourly 
intervals following the gluten challenge. Morphometric assessment of biopsies 
is carried out under light microscope using these parameters: villous 
height/crypt depth ratio, epithelial surface ECH and IEL count. This method 
has demonstrated the dose-dependent effects on small intestinal biopsies and 
has been used to study potential toxicity of cereals peptides (Dewar 2006). It is 
an invasive method that requires a qualified physician and depends on the 
























The primary aim of this study was to investigate the coeliac immunogenicity 
of ω-gliadin/C-hordein peptide and rye secalin derived peptide with small 
intestinal gluten sensitive T cell lines. These peptides have been assessed with 
T cell clones of PMBCs and demonstrated high recognition to Triticae 
prolamins.    
The secondary aim was to produce MAbs to these immunogenic peptides. This 
followed the demonstration of the stimulation in the majority of small 
intestinal gluten sensitive T cell lines when tested with these peptides.  
 
The secondary aim was also sought developing an improved assay for gluten 
quantification in foods consumption by CD individuals. The development of 
ELISA in the cocktail competition format involved MAbs previously 
generated by investigators within our group. It is hoped that the combination 
of MAbs to both gliadin and glutenin, as well as MAbs to barley and rye 
fractions would yield an improved assessment of potential gluten 
contamination of commercially available foods for individuals with CD. 
 
The null hypothesis of these studies is that both ω-gliadin/C-hordein peptide 
and rye secalin derived peptide are not immunogenic and do not stimulate 









The objectives are: 
1. To investigate the coeliac immunogenicity from potential barley and rye 
peptides identified from literature as potentially toxic to individuals with 
CD. Following the potential CD toxicity of these peptides in PBMCs, these 
peptides were assessed with sensitive small intestinal T cell lines obtained 
from CD patients. We sought to generate wheat gluten sensitive T cell 
lines (n-14), barley hordein sensitive small intestinal T cell lines (n=9) and 
rye secalin sensitive small intestinal T cell lines (n=2). 
 
2. To isolate PBMCs from CD patients’ blood that would serve as APCs in the 
in vitro study. 
 
3. To demonstrate the proliferation of sensitive small intestinal T cells in 
response to the presence of the potentially immunogenic peptides. 
 
4. To develop MAbs to potentially CD toxic peptides.  
 
5. To construct immunogens from the immunogenic peptides by conjugating 
to PPD. 
 
6. To clone the resultant hybridoma for specific Mabs, followed by culturing 
and concentrating the tissue cultured supernatant containing the MAbs. 
 
7. To characterise and evaluate the potential binding and cross reactivity of 
MAbs. 
 
8. To design an improved assay for gluten quantification in commercially 
available foods for individuals with CD including purified wheat starch 
that serves as the basis for commercially available gluten-free food. 
59 
 
9.  To establish cocktail competition ELISAs by combining available MAbs 
raised against to wheat glutenin and gliadin peptides. 
 
10. To optimise the concentrations for coating antigen, competing antigen, and 
working antibodies using sandwich ELISA for the development of more 
sensitive and specific assay for gluten quantification in commercially 
available gluten-free foods. 
 
2.3 Ethical considerations 
The ethical committee approval was granted by the Ethical Committee of St 
Thomas’ Hospital for the studies involving biopsies from CD patients. The 
LREC study number is 05/Q0702/167; the patients gave written informed 
consent. 
 
The MAb procedures were approved by the United Kingdom Home Office and 
conducted at King’s College London Biological Services Unit (BSU). The 
procedures were undertaken with the assistance from the supervisor under his 
Project Licence (70/19003) and Personal Animal Licence (70/6885). The 
animal work was classified as mild under the Home Office severity grading. 
The production of MAb is covered under the Animals (Scientific Procedures) 
Act 1986. All the procedures made to the mice were recorded and filed. 
 
2.4 Confidentiality 
All blood samples and tissues are anonymised by coding with the student’s 
initial plus an alphanumeric code. All the information collected about patients 
involved in the study was treated as highly confidential and only documented 
on the individual consent forms. The forms are stored in as secure filing 
system and database to which access is strictly limited. 
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2.5  Plans of investigations 













1) Peptides of potential immunogenicity selected from literature, 
synthesis of peptides by solid phase peptide synthesis. 
a) ω-gliadin/ C-hordein peptide 
b) Rye-secalin derived peptide 
2) Assess the peptides with gluten sensitive small intestinal T cell lines 
generated from CD biopsies. 
3) Develop MAb to those peptides found to be immunogenic and CD 
toxic in the earlier in vitro study. 
4) Develop an improved assay for quantification of gluten fractions if 
foods for CD individuals with greater sensitivity and specificity 
compared to those available. 
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CHAPTER THREE: INVESTIGATION OF CD IMMUNOGENECITY OF 




CD is mediated by inappropriate recognition of, and activation of T cells to, 
immunogenic peptides of wheat, rye and barley. Numerous studies have 
demonstrated the presence of T-cell stimulatory peptides in gliadin (Vader et al 
2002a, Vader et al 2002b, Anderson et al 2000, Arentz-Hansen et al 2000, van de 
Wal et al 1999, van de Wal et al 1998, and Sjostrom, 1998) and in glutenin (Tye-
Din et al 2010, Dewar 2006 and Molberg et al 2003). 
 
Barley and rye proteins have been known to be CD toxic, similar to wheat gluten, 
however little information is known regarding the immunogenic peptides within 
them. T cell responses to triticale proteins besides wheat gluten have been 
observed in CD patients (Tye-Din 2010, Kilmartin 2006 and Vader 2003), 
explaining the ability of barley and rye to be disease-inducing. Vader (2003) 
identified 11 homologous T cell stimulatory sequences in barley hordein and rye 
secalin, located in similar regions of the proteins. Seven of them were recognised 
by gluten specific T cell lines from CD patients.  
 
Protein fractions of barley and rye was demonstrated to induce antigenic 
reactivity in gliadin sensitive T cell lines generated from CD small intestinal 
mucosa (Kilmartin 2006) such that these graminae need to be excluded from the 
diet of CD patients. Oats are considered safe in the majority of the CD patients 




Evidence suggests that most CD immunogenic peptides are found in α-gliadin. A 
protease-resistant 33 amino acid peptide is generally thought to be the most CD 
immunodominant antigen derived from α-gliadin that is recognised by gluten 
sensitive T cell lines from HLA-DQ2 positive CD subjects. In the light of Tye-Din 
and colleagues’ study (2010), the evidence for potential epitopes in barley and rye 
has increased. 
 
The first peptide candidate in this study was ω-gliadin/C-hordein peptide 
(QPFPQPEQPFPW). This potential immunogenic peptide was identified by Tye-
Din and colleagues (2010), who tested with T cell clones of PBMCs, was shown to 
be the most stimulatory peptide in barley, wheat and rye, after the in vivo 
ingestion of these prolamins (Triticeae). T cell clones specific for this peptide 
were the most cross-reactive and recognised >50% of gliadin/hordein/secalin T-
cell stimulatory peptides (Tye-Din 2010).  
 
Perhaps the best explanation for the immunogenicity of this peptide is that the 
sequences are comprised of 2 overlapping CD-relevant T cell epitopes (Sollid 
2012, Tye-Din 2010). The first epitope is DQ2.5-glia-ω1 (Sollid 2012) or known 
as DQ2- ω-I (Tye-Din 2010) which consists of 9 amino acids; PFPQPEQPF. The 
second epitope which also consists of 9 AA (PQPEQPFPW) is known as DQ2.5-
glia-ω2 (Sollid 2012) or DQ2- ω-II (Tye-Din 2010).  Vader (2003) considered 
DQ2- ω-I as a functional homolog of DQ2-α-1 (Hor-α-9/ Sec- α-9), and a similar 
view with DQ2- ω-2, being the functional homolog of DQ2-α-2 (Hor-α-2/ Sec- 
α-2). He pointed out that the toxicity of barley hordeins and rye secalins is due to 
the presence of Hor-α-9/ Sec- α-9 and Hor-α-2/ Sec- α-2 that were recognized by 
T-cells specific to DQ2-α-1 and DQ2-α-2. In contradiction to Vader’s attribution, 
Tye-Din’s work demonstrated overlapping DQ2- ω-I and DQ2- ω-2 as being 
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responsible for the toxicity of wheat, barley and rye, instead of DQ2-α-1 and 
DQ2-α-2 (Tye-Din et al 2010).  
 
The understanding of the first peptide was further deepened by analysing its 
sequence using BLASTP (NCBI); the search yielded its closest homologies with C-
hordein and ω-secalin (rye). This is in parallel with the study by Hsia and 
Anderson, (2001) that involved isolation and characterisation of ω-gliadin genes. 
Their analysis has confirmed the relation of wheat ω-gliadin to the C-hordein 
(barley) and ω-secalin (rye).  This possibly supports the idea that this peptide 
exists in all three Triticeae prolamins, thought to exacerbate CD.   
   
The second peptide candidate was considered from both Vader’s (2003) and Tye-
Din’s (2010) studies.  A rye derived peptide: QPFPQPQQPIPQ was recognized by 
more than 80% of PBMCs donors when assessed with IFN-γ enzyme-linked 
immunosorbent spot (ELISpot) following a five day oral gluten challenge (Tye-
Din 2010). When one compares the sequence of this peptide with the aligned 
gliadin homologes in secalins (Vader 2003), it is shown that the second peptide 
lies in sequences of Sec- α-2 and Sec- α-9, thought to be homologue to DQ2-α-2 
and DQ2-α-1, respectively. The peptide sequence was aligned using Constraint-
based Multiple Alignment Tool (NCBI) and found that this rye derived peptide is 
a fraction of ω-secalin (sequence ID:gb|ACO40294.1| and ω-gliadin sequences 
(sequenceID: gb|ADF58080.1|).  
 
The immunogenicity of the selected ω-gliadin/C-hordein peptide and rye derived 
peptide could be influenced by the proline (P) residue contents. These peptides 
can probably survive in the gut and remain, stimulating T cells. It has been 
reported that the proline-rich property protects gluten peptides from degradation 
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in the gastrointestinal tract so that they will persist (Shan 2002) and increase the 
chance they will bind to HLA-DQ molecules and trigger immune response. This 
could further explain the characteristics of ω-glaidin peptides being as 
immunodominant as α-gliadin peptides having high potential to bind to HLA, 
and trigger immune response. 
 
In this chapter, the investigation CD immunogenic potential of candidate barley 
and rye peptides is described. This was sought by generating gluten-sensitive 
small intestinal T cell lines that were thought to be more pertinent to CD 
pathogenesis than PBMC lymphocytes. The focus in this study is the assessment 
of the peptides with small intestinal T cell lines sensitive to peptic-tryptic 
digested gluten (PTG).     
 
In parallel to this, sensitive T cells were also raised to peptic-tryptic digested 
hordein (PTH) and peptic-tryptic digested secalin (PTS). Biopsies from patients 
were co-cultured with digested prolamins (peptic-tryptic) to sensitise the cells. 
Proliferation assays tested the responses to candidate peptides, and other Triticeae 
prolamins. The results of proliferations assays were analysed in terms of the CPM 
of incorporated tritiated thymidine, and stimulation indices were calculated. 
Sequential to this work, MAb to the immunogenic peptides will be raised with a 
view to developing improved methods for gluten measurement. This will be 
discussed in Chapter Four. 
 
3.2 Aims 
The primary aim is to investigate the potential CD immunogenicity of the ω-
gliadin/C-hordein peptide and the rye derived peptide with gluten sensitive small 
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intestinal T cell lines established from biopsies obtained from individuals with 
CD. The secondary aim is to study the possible cross-reactivity of CD small 
intestinal gluten sensitive T cell lines with PTH and PTS. 
 
3.3 Objectives  
We wished to  
 To obtain small intestine biopsies and blood samples from CD patients  
 To isolate PBMCs from blood, freeze and use as APCs 
 To establish wheat gluten small intestinal T cell lines 
 To establish barley hordein and rye secalins T cell lines 
 To undertake T cell proliferation assays to test the immunogenicity of the 
candidate peptides 
 To study the cross reactivity between wheat gluten sensitive T cell lines 
with other cereal prolamins to confirm the presence of other shared 















Gluten sensitive small intestinal T cell lines from patients were generated in 
order to undertake T cell proliferation assays. The established T cell lines were 
tested with the selected peptides, other Triticae prolamins and the co-culturing 
antigen itself, which is either PTG or PTH or PTS. PHA which serves as a marker 
for cellular viability was also included but the results were not shown. 
 
3.4.1 Patients 
Biopsies from CD patients were sensitised to PTG (n=14), PTH (n=9), and PTS 
(n=2).  The patients used in this study were either treated with GFD or newly 
diagnosed and still consuming gluten. Ethical approval (05/Q0702/167) was 
obtained for all experiments and all patients involved had given informed consent 
before the procedures took place. Six to eight biopsies were obtained from CD 
patients. For the establishment of wheat gluten small intestinal T cell lines, the 
patients were coded with WG1, WG2 and so forth. Patients were coded as WB1 
and WR1 for barley hordein T cell lines and rye secalin T cell lines, respectively. 
The ratio of female to male patients is 3:1. The list of patients whose biopsies 











Table 3.1: List of patients recruited to generate gluten sensitive T cell lines 
 







F 32 2011 4 months DQ2 
WG2 
WB3 
F 22 2007 5 years DQ2 
WG3 
WB4 









M 64 2012 4 months DQ2 
WG6 F 24 2011 4 months DQ2 
WG7 
WB6 
F 76 n/a 42 years DQ2 
WG8 F 29 2011 4 months DQ2 
WG9 M 50 2011 3 months n/a 
WG10 F 63 2011 1 year n/a 
WG11 F 30 2010  2 years DQ2.8 
WG12 
WB7 
F 35 2010 3 months DQ2.8 
WG13 
WB8 
F 65 2012 Eat gluten  
WG14 
WB9 
F 60 2011 10 months DQ2.6 
WB2 
WR1 





The rationale for choosing the peptides in this study is explained in the 
introduction section (3.1).  The synthetic peptides were designed with 16-AA 
residues, made commercially by GenScript (New Jersey, USA) with 95% purity.  
Candidate peptides are; 
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1. Omega (ω)-gliadin/C-hordein peptide, termed as PepG 
PQQPFPQPEQPFPWQP 
 
2. Rye-derived peptide, termed as PepR 
PQQPFPQPQQPIPQQP 
 
3.4.3 Enzymatic digestion of gluten fractions-industrial gliadin 
Wheat industrial gluten (418, Batch NW652) was purchased from Roquette Ltd, 
Corby Northants, UK). Pure milled flours of barley (variety Porter) and rye 
(variety Rheidol) were obtained from Plant Breeding International, Trumpington, 
UK. Triticae prolamins were prepared by pre-washing the milled flours with 
sodium phosphate buffer (0.4 M), to remove albumins and globulins, and 
extracting with 60% ethanol using a standard protocol (Wieser 1994). 
 
The prolamins were enzymatically hydrolysed with pepsin (Sigma P0609) and 
trypsin (Sigma T1763), both attached to agarose according to the method of Bolte 
et al (1996), and others (Kilmartin 2003) with slight modification. One gram of 
wheat industrial gluten was dissolved in 50ml of 0.1mol/L hydrochloric acid 
(HCl), pH 2.0 and 105mg (4000U) of pepsin was added. The mixture was 
continuously stirred at 37°C for 2 hours and centrifuged for 20 minutes at 350 x g 
at 20°C. The pH was adjusted to 7.8 by adding 1mol/L of sodium hydroxide 
(NaOH); 1ml (25 U/ml) of trypsin suspension was then added. The mixture was 
continuously stirred and incubated for a further 2 hours at 37°C. The pH was 
then adjusted with 1mol/L HCl to 7.0. The suspension was again centrifuged for 
20 minutes at 350 x g at 20°C. Finally the digested prolamin was dried by 
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evaporation at 37°C for several days and stored in a sterile bottle at room 
temperature for future use. 
 
3.4.4 Antigen preparation 
Deamidation of peptides is crucial for T cell recognition. In these T cell studies, 
peptic tryptic prolamins (PTG or PTH or PTS) were pre-treated with tTG to 
achieve deamidation. This was prior to incubation with APCs for use in T cell 
restimulation and T cell proliferation assays. Deamidated PTG was prepared by 
adding 10µl of PTG (10mg/ml) with 135µl of 2mM calcium chloride (CaCl2) in 
PBS (Sigma, P4417) and 125µl of 200µg/ml tTG (Sigma, T5398) for four hours at 
37°C. Following the incubation, the solution was irradiated for 30 minutes to 
sterilize and stored at -20°C. Similar steps were used to prepare deamidated PTH 
and PTS mixtures. The preparation of the stock solutions can be referred in 
Appendix 1  
 
3.4.5 Isolating PBMCs from patients’ blood 
PBMCs were isolated to serve as APCs. The blood was collected from patients 
prior to endoscopy in a sterile syringe and transferred into 50ml Falcon tube(s) 
containing 100µl of heparin (1000U/ml, LEO V30814) to prevent the blood from 
coagulating. The blood was centrifuged at 800 x g for 10 minutes. The plasma 
supernatant was removed; 10ml of the remaining cell mixture was transferred to 
a 50ml Falcon tube. Twenty eight millilitres of Rosewell Park Memorial Institute 
(RPMI) medium (PAA) was added. This was mixed thoroughly, taking care to 
avoid producing bubbles. The mixture was then under- layered with 10ml of 
lymphoprep (Axis-Shield) and centrifuged at 800 x g for 20 minutes. The white 
cells contained in the ‘buffy coat’ (Figure 3.4.5), underlying the RPMI layer was 
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collected and transferred to a 50ml falcon tube. The white cell mixture was 
centrifuged at 350 x g for 15 minutes. The supernatant was carefully removed and 
the pellet resuspended in 5ml autologous serum medium (ASM) which contained 
10% heat inactivated human serum, 25µg/ml plasmocin (InvivoGen), 2.5µg/ml 
amphotericin B (PAA) and 0.01M of HN-2-hydroxyethylpiperazine-N’2-ethane 
sulphonic acid ( Hepes, Sigma H0887). 
 




3.4.6 Obtaining autologous serum 
Once the blood had been centrifuged, the clear upper layer that comprised the 
plasma was pipetted into a 15ml Falcon tube. The plasma was heated at 56°C in a 
water bath for 35 minutes to inactivate the complement proteins. The plasma was 
then centrifuged at 350 x g for 15 minutes. The plasma supernatant was collected 
into new tube and irradiated for 20 minutes (125 Gray) to be used in ASM. The 






3.4.7  Isolating T cells from in vitro gluten challenged small intestinal biopsies 
The establishment of small intestinal T cell lines in vitro was based on the 
methods of Ellis (2003). This method was sought to obtain T cells that could be 
cultured in a specific medium. Six to eight biopsies were obtained at endoscopy 
were placed in a single stainless steel grid on an organ culture plate. The sterile 
organ culture dish was prepared in advance by adding 1ml of filter-sterilised 
tissue culture water (Sigma W3500) to the outer well. The biopsies were oriented 
mucosal surface uppermost and close to each other to increase cell-cell contact 
(Figure 3.4.7).  
 




The biopsies were cultured in organ culture medium containing PTG or PTH or 
PTS (5mg/ml) as the stimulating antigen. The central well was carefully filled 
with pre-warmed organ culture medium using a syringe, until a thin layer of 
medium was drawn over the serosal surface by capillary action. The organ culture 
dish was placed inside an organ tissue culture chamber.   
  
     Biopsies 
Tissue culture water 
Organ  culture 
medium 
Organ  culture dish 
     Steel grid 
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A gas mixture of 95% O2: 5% CO2 was allowed to flow through the chamber for 1 
minute prior to sealing the chamber. The chamber was then sealed and further 
gas was introduced until a pressure of 2 psi was reached. The cultures were 
incubated for 18-20 hours at 37°C in an atmosphere of 95% 02: 5% CO2. The 
following day, after 18 hours incubation, the biopsies were harvested and 
homogenously dissected using two scalpel blades. The liquid beneath the grid was 
collected. The finely dissected biopsies were then passed through a 70µm nylon 
cell strainer (Falcon) which was placed on tube containing the organ culture 
liquid, to remove the epithelial cells and non-digested tissue. The debris 
remaining on the filter was retrieved and transferred into another 50ml Falcon 
tube. Into both tubes, ASM was added up to 10ml to re-suspend the cells that 
were then centrifuged at 170 x g for 7 minutes. The supernatant in each tube was 
discarded and the pellet was resuspended in 5ml of ASM. The tubes were 
centrifuged again at 170 x g for 7minutes. 
 
The supernatant was discarded and the pellet resuspended in 2ml of ASM. Two x 
106 irradiated (22 Gray) autologous PBMCs were added to the SIL fraction. The 
addition of PBMCs increased contact between the cells. Both suspensions were 
transferred in separate wells of a 24 well plate (Nunc), labelled as SIL and debris, 
respectively. 
 
3.4.8 Freezing down cells 
PBMCs were frozen to be used as APCs for restimulation of T cells. The 
suspension was frozen by adding drop-wise 20% ice-cold DMSO (Sigma D2650) 
in ASM, to an equal volume of cell suspension. The cells were aliqoted into 
several Nunc cryo-tubes, 2 to 5 x 106 in each tube. The cryo-tubes were placed in 
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cryo-chamber and frozen overnight at -70°C.  The following day, the cryo-tubes 
were transferred to liquid nitrogen and left frozen for indefinite storage. 
 
3.4.9 Maintenance of T-cell lines in culture 
Interleukin-2 (IL-2) was added on day three and subsequently in three day 
intervals to a final concentration of 10U/ml. The addition of IL-2 stimulates the 
growth T cells that were sensitised due to the presence of gluten in the organ 
culture medium. Medium was refreshed every two or three days depending on 
cell growth rate whilst re-stimulation was undertaken every seventh day. The 
culture was re-stimulated with 2 to 5 x 106 of autologous, irradiated PBMCs 
which were incubated with the deamidated PTG (370µg/ml) for 18 hours before 
the re-stimulation. The cell line was subsequently maintained on a weekly re-
stimulation cycle by feeding with IL-2 (to a final concentration of 10U/ml) every 
3-4 days.   
 
The growth of the culture was monitored by observing the colour of the medium. 
Rapid growth resulted in quick change of the medium red colour to yellow 
indicating the production of acid and the need for the culture medium to be 
refreshed. When cells were growing rapidly, cell suspensions were split by 
transferring either half or a third of the cell suspension to a new well. This was 
then made up to the volume of 2 ml with fresh ASM and 10% of IL-2 (200µl) was 
added. 
 
3.4.10 Re-stimulation of culture with deamidated PTG 
The cells were counted and checked for their viability prior to re-stimulation. If 
there were sufficient cells, proliferation assays could be undertaken. Otherwise, 
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cells would require re-stimulation with the antigen, that should be undertaken 
every seventh day. This interval would allow the cells to respond to the re-added 
antigen and proliferate. ASM, squeezing pipettes and 15ml Falcon tubes were 
placed on ice to cool as PBMCs were retrieved from liquid nitrogen storage. 
PBMCs were thawed under running warm tap water and immediately transferred 
to a pre-cooled Falcon tube.      
 
Next, ASM was added to PBMC drop-wisely for the first 2ml then more rapidly 
up to a volume of 10ml. The mixture was centrifuged at 170 x g for 7 minutes. 
The supernatant was discarded and the pellet was resuspended with 10ml of plain 
ASM. The suspension was centrifuged again at the same condition to get rid of 
remaining DMSO. The pellet of PBMCs was resuspended in 500µl ASM and γ-
irradiated (22-Gray). Irradiated PBMCs were used as APCs. The cells were 
transferred to a well (24-well culture plate). Five hundred microlitres (370 µg/ml) 
of deamidated PTG or PTH or PTS mixture was added and the resultant mixture 
was incubated at 37°C overnight. The PBMCs and antigen mixture was added to T 
cell cultures the next day to restimulate the T cells.  
 
3.4.11 T-cell proliferation assay 
T cells were assessed via T cell proliferation assays, in response to the presence 
deamidated PT prolamins and candidate peptides. PBMCs were thawed from 
liquid nitrogen storage to use as APCs. The PBMCs were counted using a 
haemocytometer. The number of cells required was determined by the number of 
wells used, allowing 5x104 cells per well. PBMC were γ-irradiated (22 Gray) to 
prevent the APC themselves from proliferating. APCS were incubated at 37°C, 18 
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hours for more complex antigens including deamidated PTG/PTH/PTS and 4 
hours for smaller peptides (PepG and PepR).  
 
Deamidated PTG (or PTH or PTS) was used at a final concentration of 100µg/ml 
as they are more complex proteins while shorter sequences peptides were used at 
10µg/ml to 20µg/ml due to their smaller size. The T cells and APC with PHA 
were included as positive controls at a final concentration of PHA of 10µg/ml as 
well as the T cells and APC alone as the baseline. Each test was established in 
triplicate. T cell lines for antigen reactivity were counted using a 
haematocytometer. A sufficient number of cells depended on the number of tests, 
allowing 5x104 per well. The cells were transferred to a 15ml Falcon tube 
centrifuged at 170 x g for 7 minutes and resuspended in medium, 100µl per well. 
The suspension was added to APC pre-incubated with antigen, and incubation 
was carried out for 48 hours at 37°C.  
 
One µCi/well of tritiated (3H) thymidine was added in 20µl ASM to all the wells 
and the plate was incubated further for 18 hours at 37°C. Following the 
incubation, the cells were harvested using a Tomtec Cell Harvester. Tritiated 
thymidine incorporation into the nuclei of proliferating cells was measured using 
a Wallac 1450 Microbeta Plus Liquid Scintilation Counter (Perkin Elmer Life 
Sciences, Cambridge, UK). The SI for each antigen were calculated by dividing 
the mean CPM for the T-cells plus APC plus tested antigen by the CPM for T-







3.5 Results  
Three categories of antigen sensitive small intestinal T cell lines were established 
to assess the immunogenicity of PepG and PepR. They were: 1) wheat gluten 
sensitive small intestinal T cell lines, 2) barley hordein sensitive small intestinal T 
cell lines, 3) rye secalin sensitive small intestinal T cell lines. CPM of small 
intestinal sensitive T cell lines in medium with and without antigen are shown in 
Table 3.2, Table 3.3 and Table 3.4. The SI were subsequently calculated by 
dividing the mean of CPM of triplicated samples of T cells + APCs + tested 
antigen (with antigen) by the values of T cells + APCs without antigen (blank).  
SI > 2 is considered positive (Ellis 2003).  
 
3.5.1 Statistical analyses 
GraphPad Prism 5.0 for Windows was used to analyse the results statistically. As 
the number of samples is small and the data distribution is skewed (according to 
Gaussian distribution), non-parametric Freedman and Kruskal Wallis tests were 
employed followed by Dunn's multiple comparisons tests.  
 
3.5.2 Generation of wheat gluten small intestinal T cell lines 
Fourteen T cell lines sensitive to wheat gluten were generated. These lines were 
obtained from co-culturing the biopsies of CD patients for 18h in the presence of 
PTG (5mg/ml).  The results were interpreted in two ways: one was by comparing 
the CPM, and the other, the comparison of SI for the selected peptides with PTG, 
which served as a positive control. The cells without added antigen formed the 
baseline. As shown in Table 3.2, the results are expressed as arithmetic mean of 
CPM ± SEM, the other column show the calculated SI. Tested antigen triggered 
intestinal responses in the majority of studied patients, and a heterogeneous 
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pattern was shown. Comparison of results with and without antigen is shown in 
Figure 3.1. Comparison of SI for each tested antigen is with PTG is shown in 
Figure 3.2. 
 
The response of wheat gluten small intestinal T cell lines in each patient is 
illustrated in Figure 3.3. The line-graph of two T cell lines displayed higher peaks 
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Tested antigens are PTG, ω-gliadin/C-hordein (PepG), rye-derived peptide (PepR), PTH and PTS. R(s) is number of 
restimulations, CPM is counts per minutes, SEM is standard error of mean and SI is stimulation index. 
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Tested antigens are PTG, ω-gliadin/C-hordein (PepG), rye-derived peptide (PepR), PTH and PTS. R(s) is number of 
restimulations, CPM is counts per minutes, SEM is standard error of mean and SI is stimulation index. 
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Mean CPM of triplicate wells of T cell with and without antigen (blank: APCs+T-
cells only) were compared for significance using a Friedman test (P<0.001). The 
Dunn’s multiple comparison post test determined that, in relation to CPMs, all T 
cell lines with tested antigen (PTG, pepG, pepR, PTH and PTS) were significantly 
different from T cell lines without antigen (P<0.001, P<0.001, P<0.01, P<0.05, 
P<0.001), respectively. The spread of CPMs are represented in box plots (Figure 
3.1).  
 
Figure 3.1: CPM of wheat gluten T cell lines with and without the presence of 
tested antigen 
 
Comparison of Wheat Gluten T-cell lines








































Figure 3.1: Bars are means of CPM; the error bar is standard error of means (SEM). 
The lines in the boxplots represent the median value. Significant difference are 
shown by * (P<0.05), ** (P<0.01) and *** (P<0.001). PTG is peptic tryptic gluten; PepG 
is ω-gliadin/C-hordein; peptide PepR is rye-derived peptide; PTH is peptic tryptic 




The median (SI) obtained from the all tested antigens were compared with the 
median (SI) of PTG (Figure 3.2). PTG served as positive control to demonstrate 
the specificity of the T cell lines that was used in the cultures in the beginning. 
S.I to PTG was between 2.6 to 62.6 (median=8.28). Strong responses to the ω-
gliadin/C-hordein peptide and the rye–derived peptide were displayed in most of 
the gluten specific T cell lines, with SI  varying between 2.17 to 126.95 (median = 
3.06) and 2.48 to 91.31 (median = 2.69), respectively. There was cross-reactivity 
between wheat gluten sensitive T cell lines with PTH (n=10), the SI ranging from 
3.28 to 77.54 (median= 4.2) and PTS (n=9), with SI of 2.8 to 23.16 (median = 
5.03). Responses to the substrate PHA (data not shown) were high, indicating 
that the cells were proliferating in response to this mitogen. Kruskal Wallis test 
(P<0.05) with Dunn’s multiple comparison post test determined that, the 
proliferative responses of both peptides were not significantly different from 
PTG, showing that stimulating effect of both peptides were as strong as the 
















































Figure 3.2 Each dot represents an SI for an individual assay. The lines represent the 
medians of the value for each tested antigen, ns indicates not significant, compared 
to PTG. PTG is peptic tryptic gluten; PepG is ω-gliadin/C-hordein; peptide PepR is 
rye-derived peptide (QPFPQPQQPIPQ); PTH is peptic tryptic barley hordein and 
PTS is peptic tryptic rye secalin 
 
The response for individual coeliac patients is shown in Figure 3.3. The SI for 
WG4 and WG10 to all tested antigens are markedly higher than for all other T 
cell lines. The majority of T cell lines positively responded to all tested antigens 
(SI between 2.48 to 126.95). T cell lines of WG14 did not respond to all tested 
antigen except showing positivity reactivity to PTG. Negative responses were 
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demonstrated by T cell line of WG7, WG8 and WG9 to both peptides despite 
being reactive to antigen PTG. 
 
Figure 3.3: The SI for individual patient to all tested antigens (wheat gluten 


























































Figure 3.3 Each line corresponds to SI obtained per antigen tested with 14 T cell 
lines, labelled with WG1-14. A dotted line at SI of 2 distinguishes positive from 
negative results of proliferation assays. PTG, peptic tryptic gluten; PepG, ω-
gliadin/C-hordein peptide; PepR, rye-derived peptide; PTH, peptic tryptic barley 





3.5.3 Generation of barley hordein small intestinal T cell lines 
Nine T cell lines sensitive to barley hordein were generated by co-culturing the 
biopsies of CD patients for 18h in the presence of PTH (5mg/ml) to sensitise the 
cells. The proliferative responses were analysed in term of mean CPM, and SI. 
PTH was the positive control, and blank (without the antigen) was the baseline. 
As shown in Table 3.3, the results are expressed as arithmetic mean of CPM ± 
SEM, the other column show the calculated SI. The tested antigens were shown 
to trigger heterogeneous intestinal responses in the majority of studied patients, 
particularly from both peptides.  
One barley hordein sensitive T cell line has demonstrated noticeably high 










T cells +APC 
No antigen 
T cells +APC 
PTH 
T cells +APC 
PepG 
T cells +APC 
PepR 






SI Mean CPM 
±SEM 
SI Mean CPM 
±SEM 
SI Mean CPM 
±SEM 
SI 



































































































Tested antigens are PTG, ω-gliadin/C-hordein (PepG), rye-derived peptide (PepR), and PTH. R(s) is number of 
restimulations, CPM is counts per minutes, SEM is standard error of mean and SI is stimulation index. 
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Mean CPM of triplicate wells of T cell with and without antigen (blank+APCs+T 
cells only) were compared for significance using a Friedman test (P<0.001). The 
Dunn’s multiple comparison post test determined that, in relation to CPMs, all T 
cell lines with tested antigen (PTH, pepG, pepR and  PTG) were significantly 
different from T cell lines without antigen (P<0.05, P<0.05, P<0.05, and P<0.001, 
respectively). The spread of CPMs are represented in box plots (Figure 3.4).  
 
Figure 3.4:  CPM of barley hordein T cell lines with and without the presence 
of tested antigen  
Comparison of Barley Hordein T cell lines






































Figure 3.4: Bars are means of CPM; the error bar is standard error of means (SEM). 
The lines in the boxplots represent the median value. Significant difference are 
shown by * (P<0.05), ** (P<0.01) and *** (P<0.001). PTG is peptic tryptic gluten; PepG 




The medians (SI) obtained from the all tested antigens were compared with the 
median (SI) of PTH (Figure 3.5). PTH served as positive control to demonstrate 
the specificity of the T cell lines that was used in the cultures in the beginning. 
The SI to PTH was between 2.1 to 12.43 (median=3.75). Positive responses to the 
ω-gliadin/C-hordein peptide and the rye–derived peptide were displayed in most 
of the barley hordein small intestinal T cell lines, with SI  varying between 2.77 
to 30.85 (median = 3.55) and 2.04 to 40.71 (median = 3.69), respectively. Cross-
reactivity was demonstrated between barley hordein sensitive T cell lines with 
PTG (n=9), the S.I ranging from 2.25 to 59.6 (median = 7.4) Responses to the 
substrate PHA (data not shown) were high, indicating that the cells were 
proliferating in response to this mitogen. Kruskal Wallis test (P<0.05) with 
Dunn’s multiple comparison post test determined that the proliferative responses 
of both peptides were not significantly different from PTH, showing that both 
peptides were as immunogenic as the positive control, PTH.   
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Figure 3.5: Comparison of the SI for each tested antigen 






































Figure 3.5 Each dot represents an SI for an individual assay. The lines represent 
the medians of the value for each tested antigen, ns indicates not significant. PTG 
is peptic tryptic gluten; PepG is ω-gliadin/C-hordein; peptide PepR is rye-derived 
peptide (QPFPQPQQPIPQ); PTH is peptic tryptic barley hordein. 
 
The response of individual patient’s barley hordein sensitive small intestinal T 
cell lines to all tested antigens is shown in Figure 3.6. An SI for WG5 is 
markedly higher than for all other T cell lines. The proliferative responses of 
WG5 to PepG and PepR are 5 times higher than the average. The majority of 
T cell lines positively responded to all tested antigens (SI between 2.04 to 
59.6). T cell lines of WB4 and WB9 did not respond to either peptide, but only 
to PTH and PTG.  
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Figure 3.6:  The SI for individual patient to all tested antigens (barley 


















































Figure 3.6. Each line corresponds to SI obtained per antigen tested with 9 T cell 
lines, labelled with WB1-9. A dotted line at SI of 2 distinguishes positive from 
negative results of proliferation assays. PTG, peptic tryptic gluten; PepG, ω-
gliadin/C-hordein peptide; PepR, rye-derived peptide; PTH, peptic tryptic barley 
hordein 
 
3.5.4 Generation of rye secalin small intestinal T cell lines 
Only 2 small intestinal T cell lines sensitive to rye secalin were established, 
indicated by positive SI of 2.37 and 6.21 to PTS. These lines were obtained 
from co-culturing the biopsies of CD patients for 18h in the presence of PTS 
(5mg/ml) to sensitise the cells. As the lines were raised to PTS, that antigen 
was the positive control. As shown in Table 3.4, the results are expressed as 
arithmetic mean of CPM ± SEM, the other column shows the calculated SI.  
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Table 3.4 Tested antigens are PTG, ω-gliadin/C-hordein (PepG), rye-derived 
peptide (PepR), and PTS. R(s) is number of restimulations, CPM is counts per 
minutes, SEM is standard error of mean and SI is stimulation index. 
 
The response of rye secalin T cell lines to each tested antigen is also shown in 
Figure 3.7. Comparison of medians between the tested antigens and PTS was 
not calculated as only two lines were established. Positive responses to the ω-
gliadin/C-hordein peptide and rye-derived peptide were displayed in WR1 
small intestinal T cell line only, with SI of 3.33 and 2.78, respectively. 
Surprisingly, the stimulation index to PTG, of the same T cell line has 
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Figure 3.7: The SI for each tested antigen with rye secalin sensitive T cell 
lines 

























Figure 3.7 Each dot represents an SI for an individual assay. PTG is peptic tryptic 
gluten; PepG is ω-gliadin/C-hordein; peptide PepR is rye-derived peptide; PTS is 













The primary purpose of this work was to investigate the coeliac toxicity of 
cereal prolamins peptides using gluten sensitive small intestinal T cell lines. 
Candidate peptides derived from cereal prolamins of wheat, rye and barley 
were obtained from the literature (Tye-Din 2010) and are thought to be 
immunogenic and exacerbate CD. In this piece of work, the establishment of 
in vitro assays on small intestinal T cell lines is presented together with the 
assessment of the selected peptides.       
    
In some in vitro T cell studies, the investigation of coeliac toxicity of gluten 
fractions and peptides were undertaken with wheat gluten sensitive T cell 
lines, as wheat is consumed widely in the most populations. Kilmartin (2006) 
generated gluten specific small intestinal T cell lines by co-culturing them 
with gliadin, and then restimulated them with gliadin, glutenin, barley 
hordein and rye secalins fractions. The antigenic reactivity of T cell lines 
restimulated with barley hordein and rye secalin might have been assisted 
from the earlier sensitivity to CD toxic wheat gliadin.                                         
 
In this study, we preferred to establish specific lines by directly co-culturing 
with PTG or PTH or PTS as stimulating antigens. PTG, as opposed to gliadin, 
was used as the stimulating antigen in the majority of individuals with CD. 
This was because we assumed that there are antigenic determinants present in 
HMW and LMW glutenins (Molberg 1998, Dewar 2006) that would be missed 
if gliadin alone was used. Initially, the filtered cells were not given added IL-2, 
so that the sensitisation of the cell lines was exclusively due to the presence of 
the antigen.  The cells were also exposed to non-deamidated antigen assuming 
that the endogenous tTG within the small intestinal biopsies would be 
released and active in the tissues (Molberg 2001). In wheat gluten small 
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intestinal T cell lines, PTG was appointed as a positive control to compare 
other tested antigens.  PTG was also an indicator of whether the established T 
cell lines were antigen-sensitive. We can confirm the generation of gluten 
sensitive T cell lines, not only because gluten was used to challenge the cells at 
initial stage, but also the SI has shown positivity. 
 
Besides PTG, T cell lines were derived from CD small intestinal biopsies to 
cereal prolamins of barley (PTH) and rye (PTS). This is the first study, to our 
knowledge, utilising this approach, and has demonstrated the ability of these 
prolamins to activate T cell responses in small intestinal T cell lines obtained 
from duodenal biopsies from individuals with CD. It is interesting to 
demonstrate the potential of barley and rye to sensitise small intestinal 
immune responses at an initial stage.  
 
The findings from this study further confirm that these related cereal peptides 
are equally CD toxic since they demonstrated similar effects to T cell lines 
generated with PTG. Cross-reactivity was between (i) the wheat gluten 
sensitive T cell lines with PTH (n=10) and PTS (n=9), (ii) the barley hordein 
sensitive T cell lines with PTG (n=9); (iii) the rye secalin sensitive T cell lines 
with PTG (n=2). The toxicity of these prolamins is also indicated by the fact 
that majority of the T cell lines described above demonstrated 
immunoreactivity to ω-gliadin/ C-hordein peptide and the rye secalin-derived 
peptide. The cross-reactivity shown by these lines to both peptides provides 
further evidence of the potential presence of these peptides in the Triticeae 
prolamins. This explains why barley and rye should continue to be excluded 
in a GFD. The SI results also revealed that responses to PTG are generally 
stronger than to PepG and PepR alone. This could be due to the fact that PTG 




The T cell responses to both peptides and PT prolamins may vary between 
individuals with CD (Figure 3.2 and 3.3). Gluten sensitive T cell lines of 
patient WG4 and WG10 were found to be significantly high, although the 
response was assessed only after one (WG4) or two (WG10) antigenic 
restimulation(s). In patient WG4, the stimulation index to PTG is ten times 
greater than the average SI with gluten sensitive T cells from CD small 
intestinal biopsies. Both ω-gliadin/C-hordein peptide and the rye-secalin 
derived peptide exhibited a high level of CD immunogenecity. The 
proliferative response of this line (WG4) to PTH and PTS were also very high, 
indicating T cell line from this CD individual was very sensitive to Triticeae 
prolamins. This individual had taken a GFD for >15 years.  The T cell lines 
obtained from individual WG10, exhibited significant cross-reactivity to all 
the tested antigens although low numbers of cells were observed after the first 
restimulation. This individual had commenced GFD two years previously after 
being diagnosed with CD.  It is possible that these two individuals have 
greater sensitivity to the tested antigen compared to other patients. Not all 
studied patients are sensitive to both peptides, but the majority are. 
 
Heterogenous responses were also observed with the barley hordein sensitive 
T cell lines (Figure 6). In patient WB5, the proliferative responses to PTG, 
peptide ω-gliadin/C-hordein and peptide rye-secalin derived peptide were 
high. This is unsurprising since wheat gluten-sensitive T cell lines from the 
same patient (WG4) showed high levels of cross-reactivity to all the tested 
antigens.  
 
The T cell lines sensitive to rye secalin were limited to two. Attempts to 
establish lines were made several times but it proved challenging. For 
example, the WR1 line had to be restimulated thrice before a sufficient 
number of T cells could be obtained to undertake proliferation assays.  Both T 
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cell lines specific to the rye secalin exhibited cross-reactivity to ω-gliadin/C-
barley hordein peptide, but only one of the lines reacted with the rye-secalin 
derived peptide.  This could be explained by the fact that wheat has been used 
more widely in the food industry, such that it has become more popular in the 
diet compared to rye and barley. This suggests that patients may be less 
frequently exposed to rye and barley antigens.      
 
Since the prolamins and peptides are high in proline and glutamine, the 
antigens were exposed to tTG for deamidation to enhance their CD 
immunogenicity. Several studies have demonstrated the preference and 
recognition of gliadin peptides following the exposure to tTG. Deamidation 
generates negative charges in prolamins and peptides, converting glutamine 
(G) to glutamic acid (E), thus facilitating their binding to HLA DQ2 and DQ8 
molecules. This is thought to contribute to the observed small intestinal 
responses in CD. Our initial experiments were unsuccessful probably because 
the peptides were not deamidated (data not shown). Tye-Din and colleagues 
(2010) used deamidated prolamins, preferentially recognised by peripheral 
blood T cells, and the peptides were also pre-treated with tTG. Our results in 
some way agree with Tye Din (2010), showing the immunogenicity of the 
selected peptides. However, the immune response elicited by these peptides is 










CHAPTER FOUR: PRODUCTION OF MONOCLONAL ANTIBODIES TO 




4.1  Introduction 
Single clones of hybridomas secrete a product, known as MAb that specifically 
binds to a single epitope or antigenic determinant. Ever since the development 
of hybridoma technology in 1975 by Kohler and Milstein, MAbs have been 
widely applied in diagnostic and therapeutic fields as well as targeted drug 
delivery. MAbs can be made on a large scale since the hybridomas possess the 
property of indefinite life allowing propagation and growth in tissue culture. 
Hybridomas, originating from the hybridisation of splenocytes and myeloma 
cell lines, can also be frozen for storage and recovered if a new batch of MAb 
is required. The steps of conventional MAb production are illustrated in 
Figure 4.1. 
  
In CD studies, MAbs are employed in ELISA, as the specific binding 
characteristics allow for the detection of immune triggering peptides in foods. 
This is one of the most reliable tools to screen the safety of foods specialised 
for coeliac sufferers. However, MAb production is not easy and required a 
number of considerations.      
 
The first consideration is the animal used as an in vivo donor of lymphocytes. 
A variety of animals have been used as host, but the majority of MAbs are 
derived from Balb c mice (Mitea 2008, Moron 2008, Spaniej-Dekking 2004, 
Ellis 1994 and Ellis 1989). Balb c mice have been widely used to generate 









Figure 4.1 The illustrated diagram shows the steps in conventional hybridoma 
and MAb production (modified Eryl Liddell and Ian Weeks, 1995) 
 
The second consideration is the immunisation that includes the immunogens, 
immunisation techniques and immunisation schedule. MAbs could be 
produced to particular CD epitopes or peptides, since these are recognised as 
foreign substances in the recipients. However, the peptide immunogens are 
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often too small to trigger sufficient immune response, thus they are normally 
conjugated with carrier protein.  
 
Freund’s adjuvant is the most commonly used reagent for the slow release of 
the immunogen from the point of injection. The presence of the 
Mycobacterium tuberculosis could augment the immune response of the 
recipient. For this reason, only the first dose of immunogen is emulsified in 
complete Freund’s adjuvant (CFA). The subsequent immunisations should not 
incorporate these bacteria; instead incomplete Freund’s adjuvant (IFA) is used.  
 
Several techniques for producing antibodies to toxic peptides have been 
reported, particularly to wheat gluten. Moron et al (2008) raised MAbs to a 
purified plasmid constructed recombinant protein of 33-mer polypeptide α-
gliadin (33-mer-THSP70 and 33-mer-X2-THSP70). The 33-mer peptide 
gliadin polypeptide was found to be CD toxic in vitro and in vivo (Shan 2002). 
The Balb c mice were subcutaneously immunised with a 25µg dose of 
immunogen, twice and intravenously for the third dose. In all immunisations 
emulsification in adjuvant was not used.  
 
Spaniej-Dekking and colleagues sought to develop MAbs to α-gliadin (aa 59-
71) peptide and γ-gliadin peptides (aa 142-153 and 147-159). Immunisations 
were carried out intraperitonealy with 150µg of peptide conjugated to tetanus 
toxoid (TTD) or bovine serum albumin (BSA), suspended in Freund adjuvant. 
Three following doses were given at the same concentration suspended in 
incomplete adjuvant (Spaniej -Dekking 2004). Similar attempts were followed 
years later which involved MAbs to glia-α9, glia-α20, glia-γ1, LMW glutenin-
156 and HMW glutenin. All peptides were conjugated to TTD (Mitea 2008).  
Sanchez and co-workers (2007) raised MAbs that are able to recognize a 
number of antigenic epitopes of α-, γ- and -ω-secalin molecules. The latter 
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showed the highest number of antigenic epitopes recognized by the produced 
antibody. The immunisations involved two doses of 50-100 g of crude gliadin 
(Sigma) in CFA subcutaneously and a boosting dose intravenously without 
CFA. Skeritt et al (1985) produced a heat stable ω-gliadin MAb used to 
determine gluten in raw, cooked or processed foods (Skeritt and Hill 1990). 
The sandwich ELISA assay utilizing this MAb has been employed as the 
official method for gluten quantification by the Association of Analytical 
Communites (AOAC) (Thomson 2008). 
 
The first MAb developed to non-wheat antigen was based on the ethanolic rye 
extract (Sorell 1998). The R5 MAb recognises a coeliac-toxic repetitive 
pentapeptide epitope (Osman 2001) that is present in all monomeric fractions 
of gliadin, barley hordein and rye secalin (Valdes 2003). The commercially 
avalaible detection assay kit based on this MAb has been adopted by Codex for 
quantification gluten content in foods (Codex Alimentarius 2008). 
 
Professor Ciclitira’s laboratory researchers successfully produced MAbs to 
gliadin peptides. The first MAb was raised against Frazer’s Fraction III (Frazer 
1959) by immunising Balb c mice which were restricted to GFD (Ellis 1989). A 
Bacillus Calmette-Guerin (BCG) vaccine was given to prime the mice as the 
following immunisations comprised of FIII conjugated to purified PPD. Later, 
MAbs to 54 aa (3-56) sequence of alpha-gliadin was developed (Ellis 1993) and 
demonstrated cross-reactivity to all toxic prolamins (Ellis 1994).  
 
Several years later, a MAb was produced to a 19 aa peptide of A gliadin (31-49) 
(Ellis 1998). This peptide was reported to alter the mucosal architecture of CD 
patients in remission (Sturgess 1994), when infused in vivo. Moreover, the 
same group produced MAbs to immunodominant alpha-gliadin peptide (aa 57-
75) that is known to be CD toxic (Anderson et al 2000, Fraser 2003) and also to 
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HMW glutenin (antibodies CDC3 and CDC7) found to be recognised in 
different wheat varieties (Dewar 2006). 
 
The third consideration is fusion that is the key step of hybridisation. 
Splenocytes (spleen cells) are fused with mutant myeloma cells to ensure the 
antibody could be produced indefinitely. Myeloma cell lines are generated by 
culturing in the toxic analogue bromodeoxyuridine that selects thymidine 
kinase (TK) deficient cells, or in azaguanine that selects hypoxanthine guanine 
phosphoribosyl transferase (HGPRT) deficient cells. Important features of 
chosen myelomas for hybridisationa are i) they will not produce their own 
immunoglobulin and ii) they HGPRT or TK negative, that makes them 
incapable to survive in post-fusion hypoxanthine-aminopterin-thymidine 
(HAT) culture medium.  
 
In fusion, it is possible to have the unfused and fused cells. Three types of 
fused cell populations could be: i) myeloma-myeloma, ii) splenocytes-
splenocytes and iii) myeloma-splenocytes (hybrioma). Only the third 
population is able to survive in HAT medium, which has become the selection 
system to exclude the other irrelevant cell populations. The cells obtained 
from a successful fusion possess unique characteristics from the parents, first, 
being cancerous and therefore immortal (mutant parent myeloma) and 
second, having the potential to produce the desired antibody (lymphocytic 
splenocytes).  
 
In the mechanism of HAT medium, the folic acid analogue (Aminopterin) is 
used to block the biosynthetic pathway for nucleic acid. The normal cells can 
continue to synthesize the nucleic acid using the salvage pathway. However, 
the mutant myeloma parent cell line which is lacking HGPRT, are not able to 
utilize the salvage pathway and cannot survive in the presence of Aminopterin 
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(A). The hybridomas (myeloma-splenocytes) are able to survive as the fusion 
supplies the HGPRT trait from the other parent, the normal splenocytes line. 
Hybridomas are further grown in HT after all control myeloma and 
splenocytes are dead. 
 
The final stage is selection of hybridoma. This is done by screening the culture 
supernatant that might contain the desired antibody. If the hybridoma is 
found to produce antibody of interest, the cells will be cloned to produce 
MAbs. The monoclonal cell lines will be cultured for several weeks to increase 
the harvest of MAbs production. To some extent, the MAbs could be produced 
in larger scale for the use in immunoassays screening.  
 
Chapter Three described in detail the immunogenicity of ω-glaidin/C-hordein 
and rye-secalin peptides. In this chapter, the development of MAb to those 
peptides is presented with a view to developing an improved assay for gluten 
quantification in foods designed for coeliac sufferers that will be further 
discussed in Chapter Five. The steps of MAbs production in this study were 
adapted from Professor’s Ciclitira group using Balb c mice that were fed with 
gluten free food. The immunogens were conjugated to PPD by glutaraldehyde 
and emulsified in Freund’s adjuvant. The employed immunisation schedule 
was based on Galfre and Milstein 1981, who proposed 3-5 weeks intervals, 
followed by a final intravenous injection without adjuvant, 3-4 days prior to 
fusion. The secondary subcutaneous injection was given four weeks after the 
first in the hope of obtaining the more useful class of IgG antibody, that is 








We wished to develop MAbs to ω-glaidin/C-hordein and rye-secalin peptides. 
 
4.3 Objectives  
The objectives of this study are: 
 To establish a methodology for successful immunisation of mice with 
PPD conjugated peptides 
 To optimise the concentration of immunogen sufficient to induce an 
immune response  
 To establish an immunisation schedule and optimise the interval time 
between the immunisations. 
 To clone and characterise the MAbs to immunogenic peptides 
 To study the possible cross-reactivity of the produced MAbs with other 

















4.4 Methodology  
 The chemicals, equipments and the composition of all reagents are discussed 
in details in sections where required. The immunogens were derived from the 
same peptides described in Chapter Three. 
4.4.1 Ethical consideration 
These experiments were approved by the United Kingdom Home Office and 
carried out at King’s College London (KCL) Biological Services Unit (BSU). 
The procedures were undertaken with the assistance from the supervisor 
under his Project Licence (70/19003) and Personal Animal Licence (70/6885). 
The animal work was classified as mild under the Home Office severity 
grading. The production of MAbs is covered under the Animals (Scientific 
Procedures) Act 1986. 
4.4.2 Animals and GFD 
Two breeding pairs of Balb c mice were obtained from a designated breeding 
establishment (Harlan) and placed together to produce offspring. The mice 
were fed with a purified gluten-free rodent diet (AIN-93 G, 829056) 
purchased from Special Diets Services, Dietex International Limited. The diet 
mainly consists of corn starch (39.75%), dextrinized starch (13.2%) and casein 
(20%). Previous study has demonstrated that antibody responses in animals 
that are not consuming gluten are significantly higher than in animals taking 
the standard rodent diet which contains gluten (Ellis 1998). Animals were 
cared for by the BSU staff, and inspected daily for any signs of distress and 
injury. Only one mouse died because of fighting. All of the mice were healthy 







The molecular size of peptide is one of the factors in choosing an immunogen. 
It was reported that low molecular weight antigens, that is less than 1000 
Daltons (Da) are not good immunogens, generally. The peptides chosen for 
this study are synthetic peptides, which were the same peptides as used in the 
previous T cell study (Chapter Three). These peptides have demonstrated 
immunogenicity in the majority of wheat gluten and barley hordein sensitive 
T cell lines. In addition to both peptides, mice were also immunised with 
Peptide 3, an omega gliadin peptide in native form (1948 Da). The sequence of 
this peptide is similar to the sequence of wheat ω-gliadin/C-hordein peptide, 
except the 9th amino acid is glutamine (Q). The peptides are: 
 
1) Wheat ω-gliadin/C-hordein peptide (1947.90 Da) labeled as Peptide 1- 
 P Q Q P F P Q P E Q P F P W Q P 
 
2) Rye-secalin derived peptide (1854.90 Da) or designated as Peptide 2-  
 P Q Q P F P Q P Q Q P I P Q Q P 
 
3) Wheat ω-gliadin/C-hordein peptide in native form (1948 Da) as Peptide 3- 
P Q Q P F P Q P Q Q P F P W Q P 
 
It is interesting to investigate whether a single amino acid substitution, within 
a peptide, could potentially affect the efficiency of immunisation and 







4.4.4 Conjugation of peptide with PPD 
It is necessary for the peptides to be conjugated to a larger carrier protein in 
order to generate sufficient immune response. The choice of carrier molecule 
and conjugating agent should be taken into consideration. Some examples of 
carrier proteins are ovalbumin, BSA, TTD and PPD. BSA tends to generate 
anti-BSA antibodies which might cross react in screening assays where BSA is 
used as a blocking reagent. Glutaraldehyde and carbidiimide are common 
conjugating agents used in MAb.  Conjugation of carrier to peptide using 
carbidiimide (Goodfriend et al, 1964, Eryl Liddell and Ian Weeks, 1995) was 
reported to produce unstable conjugates; they could only last for a few days in 
solution. Glutaraldehyde (G5882, Sigma, Grade 1) was used in our study that 
cross-links covalently the amino groups of the peptide and carrier.  
 
The tuberculin PPD (2T.U/0.1ml, 12-817-01, Statens Serum Institute), which 
is used in human Heaf testing was obtained from St. Thomas’ Hospital 
Pharmacy. PPD contains glycerol and preservatives, and thus required 
purification prior to the conjugation to smaller peptides. The PPD was added 
to dialysis tubing (molecular weight cut-off 1000 Da, D7884, Sigma) and 
dialysed extensively with three changes of PBS at room temperature. Each 
dialysis against PBS was done for 45 minutes to remove glycerol. After 
dialysis, the volume of PPD would slightly increase since some of water 
molecules in PBS passed through the membrane. The final volume of PPD was 
measured (10.1 ml) and four times the volume of acetone (40.4ml) was added. 
The suspension was centrifuged at 3000rpm (1200 x g) for ten minutes after an 
hour at the temperature of -70°C.  
 
The acetone supernatant was then decanted and the pellet was allowed to air-
dry. PPD pellet was weighed; the molecular weight of PPD was assumed to be 
106 
 
10,000 Da. The molar ratio of PPD: peptide was calculated as 2:1. Each peptide 
and PPD were weighed out equivalent to this ratio and dissolved in PBS to 
give a concentration of 2mg/ml of PPD. Fresh, grade 1 gluteraldehyde (G5882, 
Sigma) was added to the solution at a concentration of 0.05% and stirred for 
20 hours at room temperature. As PPD is light sensitive, the steps were 
protected from daylight, and the tubes containing the PPD-peptide conjugates 
were covered with aluminium foil during overnight stirring. 
 
Following the overnight incubation, ammonium chloride (A4514, Sigma) was 
added to a final concentration of 0.1M and stirred for a further 30 minutes at 
room temperature. The conjugate was precipitated by adding four volumes of 
acetone at -70°C for an hour followed by centrifugation at 3000rpm (1200 x g) 
for 10 minutes. The supernatant was carefully removed, not to dislodge the 
conjugate pellet. The pellet was allowed to dry for around 30 minutes, 
weighed and dissolved in normal saline to the desired concentration. The 
PPD-peptide conjugate was divided into aliquots and stored at -20°C. 
4.4.5 Preparation of immunogen- Freund’s Adjuvant emulsion 
A stable emulsion of immunogen in Freund’s adjuvant was prepared freshly 
prior to immunising the mice. Gloves and eye protection were worn whilst 
handling Freund’s adjuvant. Principally, adjuvants facilitate the slow release of 
the immunogen from the point of administration. CFA (64285, Lot 05410 MP 
Biomedicals) was used for the first injection. The second and subsequent 
injections required IFA (64286, Lot 9909H MP Biomedicals). Administration 
of both Freund’s adjuvants containing the toxic peptide could induce the 
development of granuloma; hence increase the immune response of the 
animals. The emulsion was prepared with the total volume 200 µl per mouse. 
Equal volumes of Freund Adjuvant (CFA/IFA) and immunogen were drawn 
up with a 21-G needle (NN-2150R) and placed in separate 2ml 
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interchangeable all glass syringes (SYR2064). The syringes were joined by 
attaching to a 3-way tap, with the third nozzle closed-off. The syringes were 
held in each hand and the barrels were pressed against each other, in both 
directions, alternately. The pressure was applied on the barrel very quickly 
but carefully, repeated many times until a thick viscous milk-like emulsion 
was formed.            
 The stability of the emulsion was confirmed by applying a small drop to the 
surface of a 100-ml beaker of water. The drop of emulsion remained as a 
distinct droplet, and did not spread across the water surface. The stable 
emulsion (200 µl) was then transferred to 1ml Luer plastic syringe (300013, 
BD Plastipak) and capped with a shorter 21-G needle (C0114). A syringe was 
prepared for each individual mouse.  
 
4.4.6 Immunisation procedures 
The first generation of mice offspring were introduced to a GFD early in the 
suckling stage, from mothers that were maintained on GFD. The offspring 
continued the same diet at weaning stage (3 weeks of age). Prior to 
immunisations with PPD conjugate, the mice were primed with 100µl of BCG 
vaccine (0.2-0.8 million bacteria made in Diluted Sauton SSI, Statens Serum 
Institut), subcutaneously, at 6 weeks of age. This was performed by using a 
TerumoU-100 insulin syringe with needle (BS-01H2516). The first 
subcutaneous immunisation was performed two weeks after BCG vaccination. 
The immunogen was the synthetic peptide-PPD conjugate emulsified in 
Freund’s adjuvant.   
 In previous work, antibody responses have been obtained after two 
immunisations. In this study, where titres were not adequately high, a further 
dose of peptide-PPD conjugate in IFA was given at 5 weeks later. A venous 
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tail bleed was undertaken 7-10 days after the last injection. Animals that 
exhibited the highest antibody titre were selected and given an intravenous 
booster injection (I.V) of 50µg peptide-PPD conjugate (without adjuvant) 
dissolved in 100µl normal saline. Mice were sacrificed 3-5 days later to harvest 
splenocytes, the optimal time when the relevant lymphocytes are at their peak 
of proliferation rather than antibody secretion. Splenocytes were used for 
fusion to create hybridomas, explained in detail in Section 4.4.9 
4.4.7 Mice sampling 
The first bred of Balb c mice successfully produced 15 pups from two litters. 
Only 11 mice were immunised with immunogens. The second batch of 
breeding delivered 12 pups with equal number of female to male offprings, all 
were immunised. The female and male resultant mice were separated into four 
cages, and each mouse was labelled by making an ear notch (left, right, both 
or no notch). The same way of sampling was applied when the second batch of 
litter were delivered. Since three or four mice were required for each of the 
peptide, the remaining mice were sacrificed where the splenocytes were 
harvested and used as feeder cells (see Section 4.4.11). Unimmunised mice 
were also culled as a prelude to undertaking fusion experiment. 
The distributions of mice and immunisations procedures are simplified in 




Table 4.1: The immunisations programme in the first breeding (first attempt) 
Mouse  Sex Peptide  Preliminary  
dose (route) 




M1 Male 3 300 µg in 200 µl (s.c) 300 µg in 200 µl (s.c) 1000 µg in 200 µl (s.c) No 
M2 Female 1 300 µg in 200 µl (s.c) 300 µg in 200 µl (s.c) 1000 µg in 200 µl (s.c) 50 µg in 100 µl (i.v) 
M3 Female 1 300 µg in 200 µl (s.c) 300 µg in 200 µl (s.c) 1000 µg in 200 µl (s.c) No 
M4 Female 2 300 µg in 200 µl (s.c) 300 µg in 200 µl (s.c) 1000 µg in 200 µl (s.c) No 
M5 Female 2 300 µg in 200 µl (s.c) 300 µg in 200 µl (s.c) 1000 µg in 200 µl (s.c) No 
M6 Male 1 300 µg in 200 µl (s.c) 300 µg in 200 µl (s.c) 300 µg in 200 µl (s.c) No 
M7 Male 1 300 µg in 200 µl (s.c) 300 µg in 200 µl (s.c) 300 µg in 200 µl (s.c) No 
M8 Male 2 300 µg in 200 µl (s.c) 300 µg in 200 µl (s.c) 300 µg in 200 µl (s.c) No 
M9 Male 2 300 µg in 200 µl (s.c) 300 µg in 200 µl (s.c) 300 µg in 200 µl (s.c) No 
M10 Male  3 300 µg in 200 µl (s.c) 300 µg in 200 µl (s.c) 300 µg in 200 µl (s.c) No 




Table 4.2: The immunisations programme in the second breeding (second sttempt) 
Mouse  Sex Peptide  Preliminary  
dose (route) 




M12 Female 1 1000 µg in 200 µl (s.c) 1000 µg in 200 µl (s.c) No No 
M13 Female 2 1000 µg in 200 µl (s.c) 1000 µg in 200 µl (s.c) No No 
M14 Female 3 1000 µg in 200 µl (s.c) 1000 µg in 200 µl (s.c) No No 
M15 Male 1 1000 µg in 200 µl (s.c) 1000 µg in 200 µl (s.c) No No 
M16 Male 2 1000 µg in 200 µl (s.c) 1000 µg in 200 µl (s.c) No No 
M17 Male 3 1000 µg in 200 µl (s.c) 1000 µg in 200 µl (s.c) No No 
M18 Male 1 600 µg in 200 µl (s.c) 600 µg in 200 µl (s.c) No 50 µg in 100 µl (i.v) 
M19 Male 2 600 µg in 200 µl (s.c) 600 µg in 200 µl (s.c) No 50 µg in 100 µl (i.v) 
M20 Male 3 600 µg in 200 µl (s.c) 600 µg in 200 µl (s.c) No No 
M21 Female 1 150 µg in 200 µl (s.c) 150 µg in 200 µl (s.c) No No 
M22 Female 2 150 µg in 200 µl (s.c) 150 µg in 200 µl (s.c) No 50 µg in 100 µl (i.v) 




4.4.8 Tail bleed and booster immunisation. 
The blood was collected from the immunised mice to assess the immune 
response, either the mice were adequately immunised or required further dose of 
immunisation. Each mouse was allowed to enter an appropriate size of restraint 
tube, which only left the tail outside for venous tail bleed and booster 
immunisation. The restraint tube was washed and wiped thoroughly to prevent 
cross-infection and possible stress induced by pheromone released by earlier 
mice. The tail was milked gently to encourage blood flow. A small nick was made 
at the lateral tail vein, approximately one-third along the length of the tail from 
the tail tip.       
The operator used a different gamma sterilized stitch cutter (0420, Swann 
Morton) for each tail. The blood was directly transferred to a micro-centrifuge 
tube and labeled. The blood sample was collected in the range of 10-25 µl. If the 
volume of blood was inadequate, any blood clots were wiped with a clean tissue, 
and another nick was made towards the base of the tail. Blood flow was stopped 
by applying finger pressure on soft tissue placed at the blood sampling site for 
approximately 30 seconds before mice were returned to their cages.    
The blood samples were immediately spun down in a mini-centrifuge at 
maximum speed to separate the serum. The serum was aspirated using 10-100 µl 
micropipette, and the volume was recorded. The serum was diluted with 100 µl of 
PBS and kept frozen in -20C. The mice were checked after 30 minutes and the 
next day for their general health and appearance. The sera were tested for 
antibody production using a simple indirect sandwich ELISA (see Section 4.4.9).  
Mice with positive sera shown in ELISA assays were inoculated with a final 
booster immunisation using a restrained tube was used to ease the procedure. 
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Prior to the intravenous injection, the tail was warmed with a bulb to encourage 
vasodilatation of blood vessels. The tail vein was cannulated slowly and carefully 
using 25 G (NN-2516R) short needle. Booster injection was undertaken to 
maximize antibody production, act as a further secondary immunisation of 
peptide conjugate.  
4.4.9 Assessment of antibody responses using indirect sandwich ELISA 
Indirect sandwich ELISA was mainly used in our study to test the sera collected 
from immunised mice, screen the hybridoma supernatant post-fusion and analyse 
the hybridoma supernatant of new clones. The method was a standard protocol 
undertaken by a previous researcher in our group, adapted from Kiefer (Kiefer et 
al. 1992). The volumes of coating antigen, primary and secondary antibody used 
were 50µl, washings were 250µl. Polystyrene 96-well NUNC plates were coated 
with solubilised antigen for 18 hours at 4oC. Coating antigens were: PTG in 
carbonate buffer at 25 and 50µg/ml, Kolibri gliadin in 60% ethanol at 50µg/ml or 
BSA in PBS/ tween 20 at 50mg/ml, the latter used as a negative control coating 
antigen. Since the blocking reagent contained BSA, this was to ensure that 
antibodies were not binding to the blocking agent.  
 
Following the overnight coating, the contents of wells was discarded and the 
unbound antigen was washed thrice with PBS/ 0.05 % Tween 20. Blocking 
solution was then added, incubated at 37°C for 1 hour and washed once after the 
incubation. Test sera and positive control MAb supernatants previously made by 
our group such as anti-gliadin 31-49, MAb PN3 (Ellis 1998) and anti-gliadin 56-
75, MAb CDC5 were diluted in serial doubling dilutions over the range of 1:100 
to 1:102,400. The MAb supernatants were used over the range of 1:2 to 1:4096. 
The last column of PBS served as background in determining the cut-off point. 
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For the initial screening of hybridoma supernatants and new clones, the saved 
culture media was not diluted.      
The plates were incubated for 45 minutes at 37oC. The unbound materials were 
washed away by rinsing the wells thrice with 250µl of PBS/0.05% Tween 20. The 
plates were drained by patting hard on paper towels. Rabbit anti-mouse IgG 
(A4312, Sigma) or goat anti-mouse IgM (A9688, Sigma), conjugated to alkaline 
phosphatase was used as secondary antibody prepared by diluting 1:2000 in 
PBS/0.05% Tween 20. The plates were again incubated for 45 minutes at 37oC, 
washed three times and drained.    
The final step was the addition of alkaline phosphatase liquid substrate pNpp 
(p7998, Sigma). The plates were placed in the dark at room temperature, and left 
for the colour to develop. After 30-45 minutes, O.D was read using Titretek 
Multiscan plate reader at 405 nm. The lowest concentration of serum was 
determined by choosing the O.D greater than 1.5 times the average of six blank 
wells (background). 
4.4.10 Myeloma cell retrieval and preparation 
P3X63Ag8.653 (Health Protection Agency Culture Collections) myeloma cells 
were retrieved from liquid nitrogen storage approximately three weeks before 
fusion to allow the cells to be in the log phase of growth.  Prior to the retrieval 20 
ml of RPMI medium was placed on ice for about an hour. Gloves and goggles 
were worn whilst handling samples from liquid nitrogen. Cryotubes containing 
cells were retrieved from liquid nitrogen storage, quickly warmed under running 
hot tap water. Once the ice pellet appeared to dislodge from the walls, the tubes 
were run under tap water until the content became partially liquid. The contents 
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were transferred into 15 ml Falcon tube, 1ml of cold (4oC) RPMI medium was 
added drop-wise, followed by the addition of 9ml RPMI. DMSO (D2650, Sigma) 
used for freezing the cells is detrimental at temperatures above -70°C, thus the 
retrieval was undertaken swiftly at the temperature as low as possible. The tube 
was centrifuged at 300 x g (1500rpm) for 7 minutes and the supernatant was 
discarded. The cell pellet was washed once again with 10 ml of RPMI medium 
and added with 2 ml of fresh culture medium, transferred to 1 well of 24-well 
plate and left undisturbed for several days. This step is to ensure the live cells 
would have adequate cell-cell contact to multiply.  When the cell density had 
increased, the cells suspension was expanded to few more wells and added with 
fresh medium. The cells were transferred to 50 ml culture flask. 
4.4.11 Cell culture and maintenance 
Myeloma cells were cultured in horizontal flasks for approximately three weeks 
before being used in fusion. Often, many cells adhered to the walls of culture 
flasks and required scrapping prior to refreshing the culture medium. The 
myeloma culture medium was given an elimination dose of plasmocin (25µg/ml) 
as the cells lines were established from frozen myelomas. The maintenance dose 
(12.5µg/ml) was added to hybridoma cell cultures given that the cells were 
nascent and maintained at longer period. Bacterial contamination was avoided by 
adding antibiotic besides sterilizing apparatus with gamma irradiation source 
(500Gy). Penicilin/streptomycin (100µg/ml) and gentamycin (200µg/ml) were 
added to the culture medium. Penicilin/streptomycin is affective against Gram-
positive and Gram-negative bacteria, respectively. Gentamycin is effective against 
a broader spectrum of both Gram-positive and Gram-negative bacteria and can 
overcome some strains that might have developed resistance to 
penicilin/streptomycin.   
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Fungal contamination could be prevented by the use of amphotericin B 
(2.5µg/ml) in the culture medium. However, the cell culture should be discarded 
immediately if it occurs, since the contamination could be easily spread to other 
flasks due to airborne spores. All the cultured cells were kept in an incubator 
with an atmosphere of 5% CO2. When the colour of culture medium changed 
from red to yellow, that showed the fall of pH and the depletion of nutrients in 
the medium, cells were then normally fed and the old medium was replaced with 
new fresh medium.  
4.4.12 Media preparation 
Prior to undertaking the splenectomy, several types of media were prepared. 
RPMI 1640 was mainly used as in the formulation of tissue culture media, as well 
as washing and re-suspending medium. HAT (H0262, Sigma) medium was used 
for cell selection after fusion of myeloma cells with splenocytes. After 5-7 days, 
when all cells were observed dead, except the surviving myeloma- splenocyte 
hybrids, HAT was replaced with HT (H0137, Sigma) medium. HAT and HT 
lyophilized powder were initially dissolved in 10ml of double processed tissue 
culture water (W3500, Sigma), before preparing the required media. The formula 
for each type of medium can be referred in the Appendix I section. 
 
4.4.13 Splenocyte harvesting 
The technique for splenocyte harvesting and cell fusion is extremely laborious. 
For each attempt, only one mouse was sacrificed to harvest splenocytes. The 
culling and dissection procedures were undertaken at the BSU, assisted by the 
staff. The remaining steps after obtaining the spleen were performed in laminar 
flow safety cabinet. The mouse was killed by cervical dislocation and the fur was 
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drenched in absolute alcohol. A midline incision was made to the skin and 
abdominal wall, using fresh sterile instruments for each stage, and the layers 
pinned back. The sternum was dissected to open the thoracic cavity. The murine 
heart was transected, and the pooled blood was aspirated and transferred into a 
centrifuge tube, rapidly before further dissection to avoid blood clotting. The 
serum was obtained after centrifugation using the mini-centrifuge at maximum 
speed. The serum was then frozen for use as a positive control in future screening 
assays. The peritoneum was cut to expose the abdominal viscera. 
The spleen was blunt dissected and placed immediately in double strength 
antibiotic medium for 30 minutes. In a laminar flow hood, the spleen was washed 
in single strength antibiotic medium. Two ml of single strength antibiotic 
medium was added to the spleen and both were poured carefully into a Potter-
Elvehjem tissue homogeniser. The 3 strokes of the pestle were used to pulverize 
the spleen and release the cells. The cell suspension was transferred to a 15 ml 
Falcon tube using a squeezing pipette and any large debris was left in the mortar. 
The tube was centrifuged at 300 x g for 10 minutes. The supernatant was 
discarded and the cell pellet was re-suspended in 5ml of red cell lysis buffer-
Hybrimax (R7757, Sigma) to lyse the erythrocytes followed, by under-layering 
with 2ml of FCS. This cell suspension was again centrifuged 300 x g for 10 
minutes and the pellet was re-suspended in 5ml of serum-free medium. The 
supernatant containing the contents of the lysed erythrocytes was removed. The 






4.4.14 Fusion of splenocytes with myeloma cells 
Fusion was performed subsequently after splenocyte harvesting, in a laminar flow 
safety cabinet. A mouse spleen is estimated to have 1 x 108 splenocytes.  
Therefore, myeloma cells (P3X63Ag8.653), required are between 2 to 10 x 107 per 
spleen. This estimation is based on the ratio of 2-10 splenocytes to one myeloma 
cell to get an optimal fusion. A 20µl aliquot from 15ml myeloma cell suspension 
was mixed with 20µl of 0.45% trypan blue dye and applied onto the chamber of 
an improved Neubauer haemocytometer.  
Cells were observed under microscope, only the viable cells that excluded the dye 
and appeared round and shiny were counted. Once a satisfactory count and 
harvest had been performed, myeloma cells were washed thrice in RPMI medium 
to eliminate all traces of FCS, which might interfere with fusion, and re-
suspended in 5ml of RPMI medium. A one ml aliquot of the myeloma cells was 
saved in a separate well to use as an unfused myeloma cell control well and, 
another control well was included, containing the unfused splenocytes only.  
The myeloma cell suspension was added to the spleen cells and washed again 
three times in RPMI medium to remove the remaining FCS. The cell mixture was 
pelletted by centrifugation at 300 x g (1500rpm) for 10 minutes and the 
supernatant was thoroughly aspirated using a pipette. The dry cell pellet was re-
suspended in 1 ml of PEG (P7181, Sigma, hybrimax grade) solution, pre-warmed 
at 37°C. PEG disrupts the cell membrane of the cells by reducing the surface 
tension permitting the fusion of cell membranes. The mixture was vortexed for 2 
seconds and held in warm hands for 90 seconds with continuous gentle agitation. 
 Next, one millilitre of complete medium was added drop-wise, with constant 
gentle shaking.  A further 9ml of complete medium was added slowly to dilute 
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PEG and stop the fusion process. Because of its toxicity to cells that could 
interfere with cell proliferation, any traces of PEG after fusion were eliminated 
by washing. The mixture was centrifuged at 150g (800rpm) for 5 minutes and the 
supernatant was discarded. The speed and duration of centrifugation at this stage 
were reduced owing to the fragility of the cell after fusion. The cell pellet was re-
suspended in 10 ml of pre-warmed HAT (H0262, Sigma) medium and aliquoted 
1ml/well in 24-well culture plates. To both control wells of unfused myeloma and 
spleen cells 1ml of HAT medium was added. These acted as controls for the 
effectiveness of HAT, in the presence of which both type of cells should die. The 
plates were sealed in polythene bags to aide prevention of contamination, whilst 
allowing slow diffusion of gas, and placed in the incubator with an atmosphere of 
5% CO2. 
4.4.15 Culture of hybrids after fusion 
After fusion, the cells were allowed to grow undisturbed for 7 days. Then plates 
were examined every 1-3 days to check the emergence of nascent hybrids, the 
changes in medium colour, and the presence of any contamination. Comparisons 
were made between the unfused myeloma controls well, unfused splenocytes 
control well and all wells containing the potential hybrids. Unfused splenocytes 
and myeloma are mortal and normally die after one week. If control cells were 
still alive, exposure to HAT was continued by adding approximately 1ml of HAT 
medium to all wells. Usually 7 days after initial fusion, all the cells in control 
wells were dead and the hybrids could be observed as small clumps. The hybrids 
were fed by adding 1ml HT medium, carefully so as not to disaggregate the 
colonies. The growing hybridomas were monitored over several weeks. Some 
wells would have non-hybridoma fibroblast-like cells that grew very rapidly and 
exhausted the nutrients in the medium. The yellowing of the medium was not 
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the only indicator showing the presence of hybrids. Therefore, cells were 
checked microscopically and size of hybridoma clonies was noted. 
4.4.16 Screening of hybridomas 
Although a fusion might be successful not all cells may produce the desired 
antibody. Each well comprised a pool of different hybrids that could produce non 
relevant antibodies. The objective of screening is to identify interesting hybrids 
and reject the negative wells. One hundred fifty microlitres of supernatant from 
each well was pippeted into microcentrifuge tubes and added with 30µl of N-2-
Hydroxyethyl piperazine-N'-2-ethanesulfonic acid (HEPES) (H3375, Sigma), to 
maintain the supernatants at pH 7.4 for the ELISA. The ELISA assays were 
performed using PTG or PTH as coating antigens. The class of antibody from each 
screened supernatant could also be assessed, by the addition of anti-IgG/ IgM 
secondary antibody as the detecting agent. Supernatants with positive O.D were 
chosen for single cell-cloning, particularly those with the highest ELISA reading 
but appeared as the smallest colonies. The assessment was relatively subjective. 
The previous researcher had chosen 0.8 O.D as positive, compared to a 
background of 0.2. In this study, the background reading was very low (0.071) 
hence, an O.D of 0.6 and above was considered positive.  
Hybridoma cells grow very rapidly with an exponential doubling time of 12-24 
hours. Therefore, subsequent supernatant collections and screenings were 
performed at 3-4 day intervals, providing sufficient period for the antibody to be 





4.4.17 Cloning of positive hybridomas 
During cloning, some of the positive cells were frozen down for future use, 
should the chosen samples yield unsatisfactory results. A previous researcher 
employed a very laborious single cell technique for cloning. In this study, cloning 
was undertaken by diluting the cell suspension to an average of 0.5 cells per well. 
The content of the chosen well was resuspended and the cells were counted in 
trypan blue dye, using Neubauer haematocytometer. A required volume of 
supernatant that provided 200 cells/ suspension was removed from the wells and 
pipetted into 50ml falcon tube. The small volume of suspended cells was added 
with 50ml of culture medium. The 200 cells/ 100ml medium were plated out into 
round-bottomed micro 250µl wells on a 96 well culture plate, with feeder cells 
prepared to 105 cells per ml: 200ul/well. The clones were left undisturbed for 10-
14 days. 
4.4.18 Screening of clones 
Following cloning step after two weeks, culture wells were inspected under 
microscope for the presence of growing clones.  Wells that contained only one 
emerging colony were noted. Fifty microlitre of supernatant from each well was 
removed and screened for antibody secretion by ELISA as described in Section 
4.4.9. 
4.4.19 Growth and expansion of clones 
If antibody secreting clones were successfully generated, the clones were 
transferred to progressively larger vessels and supernatant will be saved. Some 
flasks of cells are fed regularly to ensure high cell viability, and cells will be 
harvested at regular intervals and frozen down. The student has previously grown 
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anti-gliadin PN3 MAb (Ellis 1998) successfully generated by the same group 
where there cultures were grown with a gradual decrease of FCS. This was to 
obtain high purity of MAbs without the presence of immunoglobulin from FCS. 
Supernatants were irradiated and stored at -20C. If required, the hybridoma 
supernatant can be precipitated to be used in immunoassays. 
4.4.20 Precipitation of immunoglobulin 
These experiments were undertaken to obtain concentrated and purified 
antibody. The medium containing cells was spun at 170 x g for 7 minutes at 24°C. 
The supernatant which contained antibody was saved after separating it from the 
cell pellet. The saved supernatant was transferred to a new tube. The volume was 
recorded. Next, equal volume of saturated ammonium sulphate (NH4 (SO4)2) was 
added drop-wise. The colour of the solution became paler. The initial colour was 
slightly orange and then turned into yellowish. This indicated that the slightly 
acidic medium had become more acidic following the addition NH4 (SO4)2 which 
is an acidic salt. This caused a fall in the pH. As more NH4 (SO4)2 was added, the 
solution became cloudier indicating that the precipitation of protein was 
increasing. Finally, the solution was kept at 4°C for further precipitation 
overnight.      
The next day, the solution was spun down at 800 x g for 30 minutes. The 
supernatant was discarded and the pellet was saved. PBS was added at 1/10 of the 
original volume of the antibody supernatant to resuspend the pellet. The solution 
was transferred to dialysis tubing, size 25mm x 16mm (Sigma D9777) for dialysis 
against PBS. The tube can retain most proteins of molecular weight 12000 Da or 
greater.  The dialysis was carried out for 45 minutes on a magnetic stirrer, 3 
times. Each time, the buffer was changed. The solution in the membrane was 
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finally transferred to a new 15ml Falcon tube, irradiated and kept at -20°C for 
future analysis. 
 
4.4.21 Storage of cells 
Cells were frozen down for long term storage once they were growing rapidly, in 
case they are required for future use. For example, the positive hybridoma cells, 
clones and myeloma cells.  Cells were harvested, washed once in RPMI and 
resuspended in 1ml of culture medium. Cryogenic tubes, a freezing chamber, 
squeezing pipettes and freezing medium were placed on ice prior to the freezing 
process. The freezing mixture which comprised of culture medium with 20% 
DMSO was added drop-wise to the cell suspension to a ratio of 1:1. The final 
concentration of DMSO in the mixture was 10%. The cell suspensions were 
aliquoted in cryotubes (usually 1ml/ tube) and placed in a freezing chamber 
containing IPA. This was placed in the -80°C overnight and transferred to liquid 












This section describes the results of experiments in relation to the first and 
second attempt at monoclonal work. The first attempt of monoclonal work 
involved first breeding of mice (11 were immunised, 2 were unimmunised, 2 died 
because of fighting) 
The second attempt was carried out with the second batch of resultant mice (all 
were immunised). 
4.5.1 Immunisations 
4.5.1.1 First attempt 
The mice sera were tested by indirect ELISA with 25µg/ml and 50µg/ml PT gluten 
as the coating antigen. The details of the immunisation programme were 
previously explained in Section 4.4.7. The concentration for each dose was 
explained in Table 4.1. The sera assessment after the second dose is shown in 
Table 4.3. The ELISA detection dilutions after the third dose are shown is Figure 










Table 4.3: ELISA assessment (IgG), the titre of sera of mice after immunisation 
with peptides conjugated to PPD, compared to unimmunised mice  
 
Supernatant  Plate with 25µg /ml PTG Plate with 50µg/ml PTG 
Positive control- 1/25600 1/25600 
Negative control-
Unimmunized mouse 
nil Not tested 
M1-Peptide 3 nil 1/400 
M2-Peptide 1 1/400 1/800 
M3-Peptide 1 1/400 1/1600 
M4-Peptide 2 nil 1/800 
M5-Peptide 2 1/400 1/1600 
M6-Peptide 1 nil nil 
M7-Peptide 1 1/400 1/400 
M8-Peptide 2 1/400 1/400 
M9-Peptide 2 1/800 1/800 
M10-Peptide 3 1/400 1/400 
M11-Peptide 3 1/800 1/400 
 
Peptide 1= Omega gliadin/C-hordein peptide      
Peptide 2= Rye secalin derived peptide             
Peptide 3= Omega gliadin/ C-hordein peptide with Q substitution at 9th position  
Positive control=PN3 MAb 
 
A titre of 1/400, for example, means the highest dilution factor that allowed for 
readable absorbance reading. Second immunizations appeared to be insufficient 
to elicit immune response. Hence, the third dose with higher concentration of 
immunogen was inoculated (Table 4.1). Two mice were shown to be sufficiently 
immunised: 
1) M2- titre of  1/ 25600 




Figure 4.2: IgG titre of PN3 MAb (Positive Control) and serum from 
unimmunised mouse (Negative Control), on a plate coated with 25 
µg/ml PTG 
 





















The graph in the box shows the highest titre was obtained from mouse 2 (M2)’s 
serum. Mice were immunised thrice with Peptide 1. Peptide 1 corresponds to ω-
gliadin/C-hordein peptide.  
The serum titre of M2 was 1/25600. M2 was given an additional IV booster 
containing 50µg of immunogen without adjuvant. All mice were given the same 
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concentration of immunogen in the first and second dose (300 µg). However, the 
concentration of the third dose was increased to 1000 µg/ml in Mouse 2 (M2) and 
Mouse 3 (M3) only.  
 





Mice were immunised thrice with Peptide 2. Peptide 2 corresponds to rye secalin 
derived peptide. None of the immunisations were successful. All mice were given 
the same concentration of immunogen in the first and second dose of 
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immunisations (300µg). However, the concentration of the third dose was 
increased to 1000 µg in Mouse 4 (M4) and Mouse 5 (M5) only. 
 





The graph in the box shows the positive titre obtained from mouse 11 (M11)’s 
serum. Mice were immunised thrice with Peptide 3. Peptide 3 corresponds to ω-
gliadin/C-hordein peptide in native form, where the 9th amino acid is Q instead of 
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E. The serum titre of M11 was 1/12800. M11 was given an additional IV booster 
containing 50µg of immunogen without adjuvant. 
 
All mice were given the same concentration of immunogen in the first and 
second dose of immunisation (300 µg). However, the concentration of the third 
dose was increased to 1000 µg/ml in all mice, except in M10.  
 
4.5.1.2 Second Attempt 
The mice sera were tested with 25µg/ml PTG after the second dose was given. 
The details of the immunogen were previously explained in Section 4.4.7. The 
concentration for each dose was explained in Table 4.2. The sera assessment after 
the second dose is shown in Table 4.4 below. The ELISA detection dilutions after 












Table 4.4: ELISA assessment: the IgG titre of mice sera after immunisation 
with peptides conjugated to PPD (Second Dose) 
 
Supernatant  Titre 
Positive control-PN3 1/102,400 
Negative control-BSA 1/100 
M12-Peptide 1 1/6400 
M13-Peptide 2 1/3200 
M14-Peptide 3 1/3200 
M15-Peptide 1 1/6400 
M16-Peptide 2 1/3200 
M17-Peptide 3 1/3200 
M18-Peptide 1 1/6400 
M19-Peptide 2 1/12800 
M20-Peptide 3 1/12800 
M21-Peptide 1 1/6400 
M22-Peptide 2 1/102,400 
M23-Peptide 3 1/25600 
 
Peptide 1= Omega-gliadin/C-hordein peptide 
Peptide 2= Rye-secalin derived peptide 
Peptide 3= Omega-gliadin/ C-hordein peptide with Q substitution at 9th position 
Two of the highest serum titre mice were chosen for fusion 
1) M22- a titre of  1/ 102,400 against 25µg/ml PT gluten 
2) M23- a titre of 1/25,600 against 25µg/ml PT gluten 
 
Selected mice (M22 and M23) were previously immunised twice with the lowest 
concentration of immunogens that was 150µg (See Table 4.2). These mice were 
then given booster immunisation and culled. However the post-fusion plates 
(from M22 and M23) were contaminated by fungal infection.  
Using the remaining mice (M12-M21), immunisations were re-assessed by ELISA. 
As some of the mice showed a good titre, the immunisations were not repeated.  
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The following are the ELISA detection dilution graphs demonstrated after the 
second ELISA assessments (Figure 4.6, 4.7, 4.8 and 4.9). 
 
Figure 4.6: IgG titre of PN3 MAb (Positive Control) and BSA (Negative 
Control), on a plate coated with 25µg/ml PTG 
 





















Peptide 1 corresponds to ω-gliadin/C-hordein peptide.  
Mice: M12 and M15 were given 1000 µg of immunogen in the first and second 
dose. M18 received 600 µg and M21 was administered with 150 µg of 
immunogen, both were during the first and second immunisations. None of the 
mice were given additional IV booster. They were also not selected for fusion. 
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Figure 4.8:  Titre of Peptide 2, immunised mice sera on plates coated with 
25µg/ml PTG 
 
   
 
The graph in the box shows the positive titre from M19’s serum, and chosen for 
fusion. Peptide 2 corresponds to rye-secalin derived peptide. 
M19 had two immunisations with 600 µg of immunogen. This titre was obtained 
from the second assessment (no third dose was given). M19 was further given an 
additional IV booster containing 50 µg of immunogen without adjuvant.M13 and 
M16 were given the same concentration of immunogen in the first and second 
immunisations (1000 µg). 
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Figure 4.9 : Titre of Peptide 3, immunised mice sera on plate coated with 




The graph in the box shows the positive titre from M20’s serum, and chosen for 
fusion. Peptide 3 corresponds to ω-gliadin/C-hordein peptide in native form, 
where the 9th amino acid is Q instead of E.  
The concentration of immunogen in the first dose is same as the second dose. 
M20 had twice immunisations with 600 µg of Peptide 3. This mouse was given an 
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additional IV booster containing 50 µg of immunogen without adjuvant. M14 and 
M17 were given 1000 µg of immunogens. 
 
4.5.2 Hybridoma formation 
From 23 immunised Balb c mice, 6 mice were sacrificed for fusion. Two fusions 
were undertaken by obtaining splenocytes from first bred mice (M2 and M11). 
The other four were conducted during the second attempt (M19, M20, M22 and 
M23).  The presence of hybridoma in HAT medium after the death of unfused 
cells was the first indicator that the fusion was successful and hybridoma 
formation was promising. Fusions from M11 and M19 did not appear to have 
hybridoma colonies. Cells obtained from M22 and M23 fusions could not be 
cultured further, since both plates had been infected with fungus. It was observed 
that fusions from M2 (first attempt) and M20 (second attempt) might bear 
hybridoma colonies. However, the hybridoma colonies from M20 were not as 
healthy as M2. M2’s cells suspension of post fusion was aliquoted 1ml/well. From 
10 wells, only 5 wells showed potential hybridoma formation. Some had larger 
colonies at very early stage. Some were observed to contain very few cells and 
others appeared to have fibro-blast cells and macrophages. Only 2 wells of M20 
contained small colonies of cells, presumably hybridoma. Figure 4.10 shows a 







Figure 4.10: A few large colonies of hybridoma growing in HT medium. This 




4.5.3 Secretion of antibodies 
The established hybridoma colonies were screened for antibody production. 
Supernatant from each well was collected and tested for both IgM and IgG anti-
peptide antibodies. Although many large colonies were observed in several wells, 
all did not contain any antibody, except for one well from M2 and one well from 













M2 Peptide 1 5/10 1/5  No 





4.5.4 Cloning and MAb production 
Although the produced antibody was IgM rather than IgG, the cells were cloned 
using limiting dilution technique as a prelude of undertaking more monoclonal 
work in the future. This was done using 96 microtitre plate, with 0.5 cells per 
well. Cloning was only undertaken during the first attempt since the second 
attempt also produced IgM antibodies. The positive hybridomas from M2 did not 
generate large colonies following cloning. Despite the attempt to use fresh 
splenocytes, the clones did not show any growth enhancement. It is assumed that 
the clones were no longer viable after 14 days. The attempt at cloning failed, 
probably due to instability of the cells. In addition, the hybridoma did not 
produce the antibody of interest, IgG that has longer shelf-life and could be 














Two attempts at MAb production were made. Mice were maintained on GFD 
since this leads to enhanced serum immune response to the injected immunogen 
(Ellis 1998). A GFD was introduced as soon as the breeding pairs arrived. The first 
generation of offspring was breast-fed from mothers that were on a GFD, and 
they continued to consume a GFD whilst weaning. This diet will cause the 
resultant mice to be intolerant to gluten, such that they can then develop 
antibodies when they are immunised with the respective peptide immunogens.  
 
In earlier work of MAb production by our group, the operator mentioned that 
the numbers of offspring were reduced when breeding pairs were on a GFD. 
However in this study, GFD has not shown any effect on the number of litters 
produced. Fifteen pups were obtained during the first breed, of which 8 were 
female. The second breed produced 12 pups (6 males, 6 females). Male or female 
animals could be used for the procedures; however, female mice were reportedly 
preferable for immunisations due to their placid nature when housed in groups 
for prolonged times (Liddell and Weeks, 1995).  Mice were also inoculated with 
BCG vaccines before the first dose of immunogen was given to initiate the 
immune response. The initiation of immunisation should be performed when the 
animals are of between 8 to 12 weeks old. If the recipients are very young, 
immunological tolerance is often induced rather than immune response. The 
efficiency of immune system also less if the recipients are too old (Reeves 2000).  
It was thought that shorter interval between immunisations could lead to the 
production of IgM antibody (Campbell 1984). Hence, in this study, the second or 
third subcutaneous immunisation was given after four weeks, allowing the mice 
to produce appropriate immune responses. The mice were checked for 
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immunisation sufficiency 7 to 10 days after the last immunisations that was the 
third (first attempt) and second (second attempt).   
 
The tail bleed results have shown that the some mice were adequately immunised 
(Table 4.4 and Figure 4.3, 4.5, 4.8, and 4.9). The fusions were successfully 
undertaken at both attempts.  This was confirmed by the observed presence of 
cells, presumed to be hybridoma (Figure 4.10) following the dead appearance of 
splenocytes and myeloma cell after several days. However, the ELISA screening 
results of the hybridoma supernatants demonstrated IgM production rather than 
the desired IgG. The IgM class antibody is known to be relatively unstable so 
could not be used in kits designed for food screening. The IgG class is the 
antibody of interest as it has longer shelf life and is compatible with the 
immunoassay kits for gluten quantification.  
It was initially thought that a single booster injection was probably insufficient to 
stimulate the spleen directly. It has been known that some studies have included 
several booster injections (Brown 2000) and but others might exclude this booster 
injection (Spaniej Dekking, 2004). Secondly, it is assumed that the mice were not 
sufficiently well immunised. The mice might have required additional IFA 
injections before the booster injection was given (Ciclitira, personal 
communication). For each additional dose, the response of mice sera should be 
assessed. This however could not be undertaken due to regulations made by 
Home Office that only allows the maximum of four injections. 
The other explanation for this is probably the interval between the last 
immunisation with the intravenous booster was prolonged. It was possible that 
those mice have reverted to produce the primary class of antibody. In the second 
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attempt, the myeloma cells had been infected with fungal contamination. The 
culture had to be discarded and new line of myeloma had to be thawed before 
fusion could be undertaken after three weeks. Therefore, the duration between 
the last immunisation (second dose) with the IV booster was extended to more 
than four weeks.  
Despite the fact that the produced antibody is the IgM class in the first attempt, 
the cells were further grown for cloning. In previous experiments taken as a 
prelude to monoclonal work, the CO2 independent medium and RPMI medium 
were compared for the growth of hybridoma. Since the hybridoma appeared to 
grow better in RPMI, RPMI was used in this study. It is hoped in the future, 
subsequent monoclonal work will be sought using the same immunogens. If the 
MAbs to these peptides could be raised, they can be used in combination with 
other established MAbs by our group, in view of developing a more improved 














CHAPTER FIVE: DEVELOPMENT OF COCKTAIL COMPETITION ELISA FOR 




The only functional treatment for CD is permanent adherence to a GFD, strictly 
avoiding foods containing wheat, barley and rye prolamins. Many of the products 
labelled as gluten free could possibly be contaminated by traces of gluten, or 
small quantities of gluten remain trapped even after several chemical methods 
and food processing steps. This raises a question on how safe is the gluten free 
food for coeliac individuals.  
Various methods of gluten quantification have emerged but concentrated on a 
particular toxic fraction. The safety of foods for coeliac individuals really depends 
on labelling, thus the exact amount of gluten should be able to be confirmed and 
standardised. Perhaps, the coeliac consumers can self-check if a simple assay is 
developed and becomes handy at home. 
 
Several studies to assess the minimum quantity of gluten that could trigger 
mucosal changes have been undertaken. Professor Ciclitira and colleagues 
demonstrated the toxicity of gluten fraction with different doses of whole gliadin 
given to coeliac patients. Measurements were taken before the challenge and 
after 2, 4 and 6 hours by in-situ biopsy. The 10mg dose had no effect by 6 hours 
but the 100mg dose induced mild changes to villous architecture and an increase 
in IEL count by 4 hours. Gliadin doses of 500mg and 1000mg showed moderate 
and severe villous flattening, respectively (Ciclitira 1984). Coeliac patients 
appeared to be able to safely consume around 10mg, and 50mg of gluten is 
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harmful for CD individuals (Catassi 2007). A daily intake of <10-50 mg gluten is 
unlikely to cause significant histologic abnormalities (Catassi 2007, Catassi 2008) 
 
In 2008, the Codex Alimentarius Committee on Nutrition and Foods for Special 
Dietary Uses adopted a revised standard of 1) 20 mg/kg for ‘gluten-free’ labelled 
products and 2) 100mg/kg for ‘very-low gluten’ labelled products (Codex 
Alimentarius 2008). The rules were then introduced as law by the European 
Union in 2012. 
 
Gluten cannot be easily measured as it comprises gliadin, LMWand HMW 
glutenin subunits (GS). Many immunostimulatory epitopes lie within gliadin 
(Arentz-Hansen 2002, Tye-Din 2010), that could be further sub-divided to α-, γ-, 
and ω- gliadin. Each of the gliadin sub-fractions consists of distinct protein 
(Shewry and Halford 2002); hence the quantification system should include the 
total gliadin sub-fractions. Besides gliadin, it is possible that more of the 
immunostimulatory epitopes could be discovered in the less characterised 
glutenins, the LMW-GS (Vader 2002a) and HMW-GS that was demonstrated to 
be highly toxic in vivo to CD individuals (Dewar 2006). 
 
There have been several reports of enzyme linked immunoassays to detect and 
measure gluten in foods. The first known ELISA assay was based on wheat α-
gliadin and whole gliadin using polyclonal rabbit or mouse antisera. The assay for 
the whole gliadin could detect α-, β- and γ- gliadins but not ω-gliadin nor 
constituents from other toxic prolamins such as barley hordein and rye secalin 
(Windemann et al 1982, Howdle 1990). The currently available assay kits are 
based on the R5 antibody (Valdes 2003) that is able to detect all sub-fractions of 
gliadin and anti-ω-gliadin antibody (Skeritt 1991) that only recognises ω-gliadin. 
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The former has been adopted by Codex as an official method for gluten 
measurement. Although these developed assays are generally sensitive, they do 
not measure glutenin, the other toxic component of gluten (Dewar 2006). The 
commercially available assay adopted by Codex cannot correctly quantify the 
actual gluten contamination, since it relies on multipling the gliadin content by 
the factor 2.  This can inaccurately estimate gluten content. Between wheat 
varieties, there is a difference in the ratio of gliadins to glutenins present. High 
pressure liquid chromatography has demonstrated that the ratio of glutenin to 
gliadin varies between 0.2 to 5.8 times (Wieser 2003).  
 
Another complication of gluten protein detection is that of the suitability of the 
detection system to detect small protein fragments and peptides, which could be 
present in foods, even if they have undergone chemical processes and been 
labelled as gluten-free. Moreover, wheat starches and wheat-derived protein 
hydrolysates are widely used in the food industry, and may contain small CD 
toxic fragments. Sandwich ELISA can only detect larger fragments. Having these 
flaws in current commercially available systems, there is a concern for better 
assay that allows for gluten detection and quantification at very low level. A 
measurement system should correspond to each and every toxic component in 
gluten that stimulates T cells response in CD patients. In addition, the system 
should be able to even detect very small fragment of gluten protein in foods 
labelled as gluten free.  
 
We proposed to develop an improved assay based on cocktail competition format 
for gluten quantification which includes the toxic fractions, gliadin and glutenin, 
and other disease activating epitopes from barley hordein and rye prolamin. The 
potential advantages of this system are the ability of quantifying small toxic 
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fraction of peptides and the simultaneous measurement of all toxic components at 
a time regardless the size of the intact protein. This will allow for gluten 
quantification in processed foods manufactured for coeliac consumers. If this 
assay can be developed, a coeliac patient can easily check if the food is confirmed 
safe for consumption.   
 
The proposed cocktail competition assay will be developed based on combination 
of murine MAbs, successfully produced by our group. The MAbs used in cocktail 
competition ELISA were PN3 against 33 mer-gliadin (Ellis 1998), CDC5 raised 
against 56-75 gliadin peptide (Anderson et al 2000, Arentz-Hansen 2000) and 
high molecular weight glutenin (CDC7) (Ciclitira 2006a). These MAbs have been 
extensively use for gluten measurement in our laboratory.  
 
PN3 has previously used to develop a sensitive assay and was able to detect 
gliadin at 4ng/ml recognising the motif QQQPFP which is found throughout all 
Triticeae fractions as well as in avenins (Ellis 1998). The antibody CDC5 (Ciclitira 
2006b) was raised against immunodominat α-gliadin epitope that also 
demonstrated in-vivo toxicty (Fraser 2003). The cocktail of MAbs will be mixed 
with the antigen before adding to the pre-coated competing antigen on the 
ELISA plate. The value obtained from a single and multiple MAbs (combination) 
is then compared. It is assumed that the cocktail (combination of MAbs) will 
generate a greater specificity and sensitivity of quantified gluten in foods 








The aim is develop an improved cocktail competition ELISA assay for gluten 
quantification in purified wheat starches. 
5.3 Objectives 
The objectives of this study are: 
 To determine the most suitable MAbs combinations in cocktail 
competition ELISA,  in a view to develop gluten standard for reference for 
gluten quantification in starches  
 To extract gluten protein and peptides from purified wheat starches 
 To optimise the concentration of coating antigen, MAbs, and competing 
antigen using simple sandwich ELISA 
 To quantify the total value of gluten (corresponds to gliadin and glutenin) 
in wheat starch using the cocktail competition ELISA 
 To compare the value of gluten obtained from assays using multiple MAbs 











5.4.1 Preparations of buffers and reagents 
All of the buffers used in this experiment were prepared using deionised water 
from a Mili-Q purification system (Milipore Bedford, USA). The Tris (2-
carboxyethyl) phosphine hydrochloride (TCEP) buffer contains 40% (v/v) of Tris-
HCl solution (50mM, pH 7.4), 0.1% (w/v) TCEP reducing agent and 60% (v/v) of 
glycerol as the extractor solvent. The Tris-HCL solution was prepared by 
dissolving approximately 2.422g of TRIZMA Base (T6066, Sigma), and adding 
with 2.76ml of 6N HCl (Scharlau, AC0752) in deionised water up to 400ml. The 
pH was ensured to be 7.4. Sixteen millilitres of Tris-HCL solution was pipetted 
into a small Schott bottle. Approximately 0.04g of TCEP powder was added and 
mixed until it was dissolved. Subsequently, 24ml of glycerol was added and 
continued with further mixing until everything was completely liquefied. The 
buffer was stored at room temperature. 
 
Carbonate buffer (0.05M, pH 9.6) was prepared by dissolving the contents of one 
carbonate-bicarbonate buffer capsule (C3041, Sigma) in 100 ml of deionised water 
and measuring the suitable pH. This buffer was used in the preparation of coating 
antigen (PTG). We have previously used 60% alcohol to dilute kolibri gliadin to 
the desired concentration. However the diluent was changed in this study since 
the antigen are soluble in water based buffers. 
 
PBS-Tween (PBS-T) buffer (0.01M, pH 7.4) was prepared by dissolving 5 PBS 
tablets (P4417, Sigma) in 1000 ml of deionised water and adding 0.05% (500 µl) of 
Tween 20 (663684B, VWR International Ltd, Lot 84137915). This buffer was used 
in washing steps and diluting MAbs to the desired concentration.  All steps 
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required three washes, except in the competition ELISA, the washing step after 
blocking. Washing was done by thorough rinsing with 250 µl of PBS-T buffer. 
 
Blocking agent was prepared by dissolving 1% of BSA in PBS-T buffer. The 
mixture was mixed on magnetic stirrer, divided into aliquots, irradiated and 
stored in -20°C for future use. Prior to undertaking ELISA assays, the blocking 
agent was placed in the incubator to warm. Blocking agent was used in the assays 
to block non-specific binding sites after coating; any unbound antigens will be 
eliminated during washing. 
 
The primary antibodies in these assays were MAbs developed previously by our 
group. In competition ELISA, the antibodies were prepared just before the 
competition step by diluting to the desired concentration with PBS-T buffer. In 
the case of optimising the antibody concentration, MAb was added to the first 
well of the microtitre plate and serial doubling dilutions were made with PBS-T. 
The secondary antibody, antimouse IgG-alkaline phosphatase (A4312, Sigma) was 
prepared at the concentration of 1 in 2000 with PBS-T. The liquid substrate pNpp 
(P7998, Sigma) did not require any dilution and added directly after washing.  
5.4.2 Preparation of murine MAbs 
Murine MAbs against gliadin and glutenins were successfully developed by our 
group. PN3 (Ellis 1998) is a murine anti-peptide monoclonal raised against a 19-
amino-acid A-gliadin peptide, known to cause an innate immunological responses 
in the small intestinal mucosa of coeliac patients (Sturgess et al. 1994). CDC5 was 
developed to an α-2-gliadin peptide amino acids 56-75 (Anderson 2000, Arentz-
Hansen 2000) and cross reacts with barley and rye. CDC7 was generated against 
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high molecular weight glutenin-GS 1Dy10 subunits (Ciclitira 2006a). The 
methods used for the production of MAbs were similar to the one described in 
Chapter Four.  
5.4.3 Preparation of antigen 
Coating antigen is one of the main components in enzyme immunoassays. Gluten 
was chosen in this study since it contains both gliadin and glutenin. However the 
choice of gluten varied. Three types of gluten were taken into consideration; 1) 
Gluten extracted with TCEP buffer, 2) gluten digested with enzyme pepsin and 
trypsin (PTG) 3) digested PT gluten but further dialysed and desalted. TCEP 
extracted gluten could not be measured by bicinchoninic acid (BCA) Protein 
Assay Reagent for protein concentration because of the presence interfering 
substance (glycerol) in the buffer; hence, the concentration of the coating antigen 
could not be furthered optimised. The second type of gluten (PTG) had already 
been prepared in the earlier studies and described in detail in Chapter Three. The 
third type of gluten might contain higher purity since salts would be eliminated 
from the sample.  
 
The dialysis of PTG was undertaken with Spectra/ POR cellulose ester sterile 
Dispodialyzer (Z36,837-7, Sigma), according to the manufacturer’s instructions.  
Prior to transferring the sample into the dispodialyzer, the 0.1% sodium azide 
preservative solution was removed and small amount of deionised water was 
dispensed into the membrane to rinse. In this experiment, the operator has 
inserted only 1ml of the PTG sample assuming that some of the dialysate might 
diffuse in during dialysis and the volume would expand. The dispodialyzer 
membrane was allowed to soak vertically and dialysed against deionised water 
(dialysate) for 45 minutes. After the dialyses, the sample appeared to have 
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precipitated and settled mostly at the bottom. Protein quantification was 
attempted to compare the dialysed and non-dialysed PTG. However, the results 
of the dialysed PTG were doubtful since the precipitates did not dissolve in the 
solution.  
 
The non-dialysed PTG was finally chosen and used in all ELISA assays 
undertaken in this study.  PTG was dissolved in deionised water and analysed for 
protein concentration using BCA Protein Assay Kit (Novagen), against BSA as 
standard. The BCA assay is based on the detection of copper ions Cu+1 reduced 
from Cu2+ in an alkaline condition. However, this kit cannot be employed if the 
protein solution contains some incompatible substances such as glycerol and lipid.  
 
Before the protein concentration of PTG was determined, BSA standard was 
prepared according to the manufacturer guidelines. A BSA standard of 2mg/ml 
was provided in the kit and was diluted with deionised water to the final 
concentration of 1000µg/ml, 500µg/ml, 250µg/ml, 125µg/ml, 25µg/ml and 0µg/ml. 
Deionised water was used as the diluents since the same buffer was used to 
solubilise the PTG. 
 
BCA working reagent was prepared by mixing 50 parts of BCA solution with 1 
part of 4% Culpric Sulfate. The sample was diluted to multiple concentrations 
with deionised water and prepared in triplicates. Protein measurement was 
carried out in micro-scale assay that required only 25µl of protein sample in each 
well and measurement could be conveniently done on a 96-well plate at the same 
time. Twenty five microlitres the BSA standard or protein sample (PTG) was 
pipetted triplicate into individual wells of a 96-well late. Approximately 200µl of 
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BCA working reagent was added to each well. The plates were covered with 
parafilm and shaken on plate shaker for 30 seconds.  
 
Next, the plates were incubated at 37°C for 30 minutes. The plates were allowed 
to cool at room temperature before reading at 562 nm on Spectramax Plus 
(P02359, Molecular Devices) reader. The correct absorbances were obtained by 
subtracting the absorbances of the blank standard (water only) from the 
absorbance of measured standard or protein samples. The corrected absorbances 
were plotted against the concentration of BSA standard to generate the standard 
curve, as shown in Figure 5.4.3   
 






5.4.4 Extraction of  purified wheat starches 
The purified wheat starches A, B and C were obtained from Transia Gluten Test 
Kit, namely starch A (less than 100mg/kg gluten content), wheat starch B (300-
600mg/kg gluten content) and wheat starch C (1000-2500mg/kg gluten content). 
Each starch was extracted individually. Approximately 100mg of starch was 
weighed into 1.5ml of Eppendorf tube and added with 1ml of TCEP buffer. The 
starch was mixed with a small spatula to avoid it from sticking to the walls of the 
tube. In this study, 12 tubes were prepared at a time equivalent to approximately 
1200mg of starches in 12 ml of TCEP buffer. The tubes were vortexed for 30 
seconds to increase the homogeneity and inverted occasionally. Next, the tubes 
were placed in pre-heated water at 85°C for 8 minutes. At this stage, gloves and 
goggles should be worn since some the tubes might pop out. The tubes were 
allowed to cool down before being centrifuged (micro-centrifuge) for 3 minutes 
at maximum speed 13000rpm at room temperature. The supernatants were 
carefully collected from each tube using a micropipette and transferred into new 
low-binding protein tube for long-term storage. The extracted starches were 
irradiated before storing in the fridge. 
 
5.4.5 Optimisation of reagents concentrations 
Prior to performing competition ELISA assays, the concentrations of coating 
antigen and working primary antibodies (MAbs) were optimised by checkerboard 
ELISA titrating assays. The steps of this direct ELISA is illustrated Figure 5.4.5 
below. The optimisation of coating antigen was started with the highest 
concentration of 50 µg/ml followed by lower concentrations of 25 µg/ml to 
0.00625 µg/ml. The plates were coated with 50 µl/well of prepared antigen, and 
left at 4°C for 18 hours. The antigen solution was discarded and wells washed 
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thrice with 250µl of PBS-T. The next step was the addition of blocking agent (the 
preparation is described in details in Section 5.2.1) to block the unbound sites, 50 
µl of the blocking agent was pipette into each well and incubated at 37°C for 1 
hour. The plates were washed thrice before adding 50 µl of each of the MAbs, 
separately. MAb was initially prepared at 1/10 and added in the first well of each 
row (pre-coated with different concentration of coating antigen, explained above) 
and serially diluted with PBS-T across the columns of the plate (concentrations 
reduced to 1/20 to 1/2560). The last well contained PBS only, to act as 
background. The plates were incubated at 37°C for 1 hour. Again, the plates were 
washed thrice before adding 50 µl of secondary, detection antibody, anti-mouse 
IgG alkaline phosphatase (A4312, Sigma), prepared by diluting to 1 in 2000 with 
PBS-T. Following the 45 minutes incubation at 37°C, the plates were washed and 
added with 50 µl/well of substrate pNpp.  The plates were left in the dark, at 
room temperature for 40 minutes, to allow colour formation. The plates were 































1) Coat antigen to plate, at 4C overnight 
2) Block the unbound sites with blocking agent 
3) Add primary antibody 
(MAbs PN3 or CDC5 or CDC7) 
4) 
Add enzyme-labelled anti-imunoglobulin 
(Secondary antibody-detection antibody) 
5) Add enzyme substrate, colour development could 
be observed after incubation  
 Wash three times with 250 µl of PBS-T 
Wash three times with 250 µl of PBS-T 
Wash three times with 250 µl of PBS-T 
Wash three times with 250 µl of PBS-T 
CDC5 is MAb raised against 56-75 α-gliadin peptide, CDC7 is MAb raised against 
HMW-GS 1DY10 subunit, PN3 is MAb raised against 19aa A-gliadin peptide 
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From the observed absorbance result, the optimum concentration of coating 
antigen is based on the signals shown even at very low concentration of MAb.  
Two of the lowest concentrations of the coating antigen were chosen for further 
assessment. The concentrations of MAbs were further optimised by repeating the 
assays with the chosen concentration of coating antigens. The optimum 
concentration of MAbs were selected and reassessed with competition ELISA. 
5.4.6 Generating gluten standard curve for quantitative competition ELISA 
Before a gluten standard curve was generated, competition ELISA assays were 
continued to choose the most suitable concentration of coating antigen, working 
primary antibodies and competing antigen. The selections of concentration were 
initially narrowed down in the direct ELISA assays as described in Section 5.4.5. 
In the competition ELISA assays, assessments were primarily undertaken on both 
chosen coating antigens (1.5µg/ml and 2.5µg/ml).      
The concentration of MAbs varied. For example, PN3 antibody was best used at 
1/160 whereas CDC7 was prepared 1/20. In addition, several experiments were 
undertaken to optimise the concentration of competing PTG antigen. The 
concentration was started with highest concentration of 2000 µg/ml and serially 
diluted to half of the concentration with PBS. After successive of experiments, 
the working concentrations were chosen in the range of 100µg/ml to 
0.0976µg/ml, in doubling dilutions. The plates were coated with the PTG at room 
temperature for 1 hour. The concentration of the coating antigen were finalised 
to be 1.5µg/ml in all competition ELISA assays undertaken. The volume of all 
reagents and samples were 50 µl, unless otherwise stated. Each step required 
thrice washing with 250 µl of PBS-T except after blocking. The plates were 
blocked with blocking agent at 37°C for 1 hour, and the contents were removed 
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by hard shaking. Whist blocking, the pre-competition steps were undertaken by 
mixing equal volumes of MAbs and working antigen in micro-centrifuge tubes, 
incubated at room temperature for 1 hour. MAbs were prepared at twice the 
determined concentration. For instance, if the MAb optimal concentration was 
1/160 in direct ELISA assays, the concentration of the antibody would be 
increased to 1/80 (twice the concentration) in competition ELISA. During the 
pre-competition steps, the concentration of the MAbs would be diluted half by 
the presence of the competing antigen, which was also prepared double the 
required concentration. In this case, the starting concentration of competing 
antigen was 200µg/ml, so that it would be diluted to 100µg/ml (desired starting 
concentration) when the same volume of MAbs was added.  
After blocking, the MAbs and antigen mixture were added to the wells and the 
competition step was allowed at room temperature for 30 minutes. After washing, 
the detection secondary antibody (1/2000) was added and the plates were 
incubated at 37°C for 45 minutes. Finally substrate pNpp was added and the plate 
left in the dark, room temperature for 30 minutes. The plates were read at 405 
nm with the Mikrotek plate reader. The gluten standard curve was generated by 
plotting the observed absorbance reading against the concentrations of competing 

















Wash three times with 250 µl of PBS-T 
Wash three times with 250 µl of PBS-T 
Coat antigen to plate, at room temperature for 1 hr 50% volume of MAb 
OR OR 
50% volume  
of antigen 
CDC5 PN3 CDC7 PTG  
Pre-Competition Step 
1) 
2) Block the unbound sites with blocking agent 
+ Pre-competition step 
3) 
4) 
5) Add enzyme substrate, colour development could 
be observed after 50 minutes incubation  
Add enzyme-labelled anti-imunoglobulin 
(Secondary antibody-detection antibody) 
Add the MAbs-antigen mixture; incubate at 
room temperature for 30 minutes 
Wash three times with 250 µl of PBS-T 
OR OR 
Whilst blocking, pre-competition step by 
incubating MAbs with antigen at RT for 1 hr 
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5.4.7 Generating gluten standard curve in cocktail competition ELISA 
The steps in cocktail competition ELISA were similar to competition ELISA, as 
explained in detail above (Section 5.4.6). However, during the pre-competition 
steps, two MAbs were combined before adding the antigen. The concentration of 
each prepared MAb should be 4 times more than the concentration used in the 
direct ELISA. For instance, if the MAb was optimal at 1/160 in the direct ELISA 
assays, the concentration of the MAb would be increased to 1/40 (4x 
concentration) in the competition ELISA.  During the pre-competition steps, the 
concentration of the individual MAb would be diluted half by the presence of the 
other MAb and further half diluted with the presence of antigen.  The simplified 







Figure 5.4.7:  Steps in competition ELISA (Cocktail Format) 









Add the MAbs-antigen mixture; incubate at room temperature for 30 minutes 
Add secondary enzyme-labelled anti-immunoglobulin (detection antibody) 
 Wash three times with 250 µl of PBS-Tween 
Add enzyme substrate. Colour development could be observed after 50 minutes incubation  
Wash three times with 250 µl of PBS-T 
Whilst blocking, pre-competition step was carried out by incubating MAbs with antigen (PTG) at RT for 1 hour,for an example; CDC5 
MAb + CDC7 MAb added to the antigen 
1/2 1/2 




Wash three times with 250 µl of PBS-T 
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The summary of the used concentrations in direct, competition and cocktail 
competition ELISA is simplified in the Table 5.4.7 below. 
Table 5.4.7: Summary concentrations of MAbs in different ELISA format 






 Two MAbs combined 
PN3 1/160 1/80 1/40 
 
CDC5 1/40 1/20 1/10 
 




5.4.8 Quantification of gluten in purified wheat starches 
Single competition and cocktail competition ELISA assays were undertaken 
simultaneously on the same plate to quantify gluten in all types of starches. 
Basically each assay consists of gluten standard for reference, individual or 
combined MAbs and starches as samples to be analysed. The methods of 
preparing the assays were described comprehensively in both Sections 5.4.6 and 
5.4.7.  Starches were extracted at 100mg/ml, irradiated and kept in at 4◦C for 
longer storage. Initial concentration in all assays is 100mg/ml that was the 
absolute starch solution without any dilution.  
 
Then, the starch was serially double diluted PBS to obtain concentration of 50 
mg/ml, 25 mg/ml…0.0975 mg/ml. The plates were coated with 1.5 µg/ml of PTG, 
left at room temperature for 1 hour. Next, the plates were added with blocking 
CDC5 is MAb raised against 56-75 α-gliadin peptide, CDC7 is MAb raised against 
HMW-GS 1DY10 subunit, PN3 is MAb raised against 19aa A-gliadin peptide 
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agent, incubated for 1 hour then added with MAb-antigen mixture. The example 




Figure 5.4.8: An example of a plate for gluten quantification using CDC5 and CDC7 MAbs 
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5.5.1 Coating antigen 
The checkerboard titration revealed the optimal conditions for assays based on 
use of PTG as coating and competing antigen. For single competition ELISA, the 
best concentrations for coating antigen were 1.5µg/ml (Figure 5.5.1.1) and 
2.5µg/ml (Figure 5.5.1.2). 
 








CDC5 is MAb raised against 56-75 α-gliadin peptide, CDC7 is MAb raised against 
HMW-GS 1DY10 subunit, PN3 is MAb raised against 19aa A-gliadin peptide 
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In cocktail competition ELISA (combined 2 MAbs), the most optimum 
concentration was 1.5µg/ml (Figure 5.5.1.3)  
 
5.5.2 Working concentration of competing antigen 





CDC5 is MAb raised against 56-75 α-gliadin peptide, CDC7 is MAb raised against 
HMW-GS 1DY10 subunit, PN3 is MAb raised against 19aa A-gliadin peptide 
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5.5.3 Working concentration of MAbs 
MAbs labelled as PN3, CDC5 and CDC7 were precipitated from the stored 
hybridoma supernatant. The best dilution for MAbs to be used in pre-incubation 











CDC5 is MAb raised against 56-75 α-gliadin peptide, CDC7 is MAb raised against 
HMW-GS 1DY10 subunit, PN3 is MAb raised against 19aa A-gliadin peptide 
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5.5.4 Real sample analysis 
Standard solution of gluten over a range of 0.195-100µg/ml was assayed on all 
plates. The amount of gluten present in each wheat starch was calculated by 
comparing the curve of starch parallel to the curve of gluten standard. From that, 
the concentration of gliadin and glutenin in starch could be calculated.  
The combination of MAbs for cocktail competition ELISA format is as follows: 
1) CDC5 plus PN3 
2) CDC7 plus PN3 
3) CDC7 plus CDC5 
The first combination was undertaken during a preliminary study and 
subsequently excluded since the assay quantified gliadin only, thus the total 
gluten content was not obtained (Table 5.5.5.1). Amidon C has been shown to 
contain the highest amount of gliadin in any cocktail competition ELISA assays. 
The lowest gliadin content was observed from starch Amidon A that was slightly 
over the recommended gluten-free label of 20mg/kg, which would increase when 
glutenin is taken into consideration.  
 
Table 5.5.5.1:  Gluten concentration in wheat starches using MAbs 

















Amidon A 21 17 28.8 
Amidon B 60 23 43.32 
Amidon C 117.9 75 178.6 
166 
 
The next attempt of cocktail competition ELISA assay was to combine CDC7 with 
PN3, which corresponds to glutenin and gliadin, respectively (Table 5.5.5.2). 
Although the Amidon A demonstrated the lowest gluten content, but the value 
exceeded the maximum recommended 20mg/kg. However the result was in 
agreement with the manufacturer’s measurement that is less than 100mg/kg. In 
addition, the Amidon B demonstrated the slightly higher than the recommended 
low gluten level (100mg/kg), but was again within the manufacturer’s estimation 
of 100-200mg/kg, when the individual quantification was combined. Amidon C 
has demonstrated over 100mg/kg of gluten content, although less than the 
manufacturers estimate of over 1000mg/kg. The value of gluten quantified by the 
combination of MAbs (Cocktail ELISA) is considerably less than the summation 
of the two single antibody assays. 
 
Table 5.5.5.2:  Gluten concentration in wheat starches using MAbs 





















Amidon A 25 33 58 36.7 
Amidon B 83 38 121 51.2 
Amidon C 180 159 339 114 
 
The final cocktail competition ELISA involved combination of CDC5 and CDC7, 
both cross react with different gluten toxic fractions. The value of quantified 
protein was more reliable in terms individual quantification, the summation of 
individual quantification and cocktail format (Table 5.5.5.3).  
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Table 5.5.5.3:  Gluten concentration in wheat starches using MAbs 





















Amidon A 16.1 33 49 20 
Amidon B 1291 333 1624 484.2 
Amidon C 1545 405.67 1950.67 777 
 
The example of gluten standard curve using CDC5+CDC7 combinations to 

















Figure 5.5.5.4: An example of gluten quantification using CDC5 +CDC7 






The first (CDC5 plus PN3) and second (CDC7 plus PN3) combination were finally 
excluded in this study due several reasons that will be explained in the discussion 
section. The results for both attempts were shown but not further used in assays 
for gluten quantification. The third combination (CDC7 plus CDC5) was intended 
to be used in quantification in other commercially available foods produced for 




CDC5 is MAb raised against 56-75 α-gliadin peptide, CDC7 is MAb raised against 




The aim of this work was to develop improved assays for gluten quantification in 
foods for individuals with CD. In our assays, the standard used for our study was 
PTG. It was intended for both CDC7 and CDC5 MAbs cross reactivity to give 
more accurate value of total gluten content. We did however attempt to use 
TCEP extracted gluten as a standard. However, the concentration of protein in 
the TCEP extract could not be measured by BCA assays, as the extraction buffer 
contained glycerol that interfered with the absorbance reading  
       
We have optimised the concentration of coating antigen, competing antigen and 
MAbs were optimised as previous studies have used different reagents. The pre-
incubation times were compared between 30 minutes and 60 minutes, and the 
latter was finally chosen. The standard curve was prepared using the range 
between 0.195 and 100µg/ml. The step after coating was blocking in the 
incubator. Whilst blocking step, MAbs and PTG were pre-incubated together 
before added to the wells containing coated antigen. This was then followed the 
addition of secondary antibody alkaline phosphatase.  
 
Two of the major disadvantages of currently available ELISA assay systems are 
lack of accuracy and unsuitable for detection of small peptides. The currently 
adopted system randomly estimates the value of gluten by assuming the 
percentage of glutenin is as much as gliadin, therefore the obtained value of 
gliadin is multiplied by two.  Besides, these methods are based on sandwich 
ELISA that could only usable for the detection of larger protein fragments. The 




Our results have shown that all three type of purified starches contained different 
level of gluten. Concerning wheat starches have been used widely for the basis of 
GF products, it is important to measure the toxic components to ensure they are 
suitable for the CD individuals’ diets.  It was anticipated that wheat Amidon C 
contains the highest content of gluten followed by Amidon B and Amidon A. The 
provided Starch C could contain the unacceptable high gluten content.  
 
What is interesting/ peculiar about this data was that, the combination of MAbs 
in cocktail ELISA did not yield a higher value of gluten compared to 
quantification using individual Mabs. It was found, on the other hand, the 
summation of individual quantification could generate higher value, in contrast 
to what have been predicted. Since gluten comprises both gliadin and glutenin, it 
was expected that the value gluten should be higher than the value of gliadin 
alone. Since CDC5 recognises gliadin epitopes only, and CDC7 recognises only 
HMW glutenin epitopes, epitope masking or steric hinderence could not be the 
cause of the lower values found in the cocktail assay. Despite of this finding, our 
assays could still represent as an improved system since both toxic components 
were measured at once. These improved assays could probably recognise small 
protein fragments, hence applicable for gluten quantification in commercially 
available CD specialised foods.  
 
Preliminary experiments were undertaken to compare the MAbs combination 
that gave the best yield of gluten content in starch. The initial attempt to 
combine CDC5 with PN3 was found to be irrelevant and unsuitable in this study 
since that assay could only quantify gliadin, but not glutenin.  
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The combination of PN3 (anti-gliadin) and CDC7 (anti-HMW-GS) was also taken 
into consideration. However, the result obtained from the combination of both 
Mabs, compared to the summation was not as high as the CDC5 with CDC7.  
 
Combination of CDC5 (anti-gliadin) with CDC7 (anti-HMW-GS) yielded the best 
result for gluten quantification in all purified wheat starches. The CDC7 has been 
shown to react with wheat, rye and barley by our group (Ciclitira 2006a).  As this 
MAb was raised against HMW-GS, it is possible that the sequence recognised by 
CDC7 is not distant to rye and barley high molecular weight prolamins, known as 
HMW secalins, and D hordeins, respectively. The quantification of glutenin using 
this antibody is not only limited to wheat-derived products or rendered wheat 
starch gluten free foods, but further screening could possibly be done in foods 
contaminated with rye and barley. Our results revealed that even the purified 
wheat starch A contain gluten more than 20mg/kg or 20ppm. This is important to 













CDC5 is MAb raised against 56-75 α-gliadin peptide, CDC7 is MAb raised against HMW-
GS 1DY10 subunit, PN3 is MAb raised against 19aa A-gliadin peptide 
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6.1 General Discussion 
Individuals with CD need to comply with a GFD as the basis of their treatment.  
Gluten was previously known as wheat gluten that is comprised of gliadin and 
glutenin proteins. It is now increasingly accepted as the generic term for CD toxic 
proteins in wheat, rye and barley; that represent. These proteins contain 
significant quantities of proline and –glutamine residues. Wheat, the gliadin 
proteins can be subdivided into α-, γ- and ω-gliadins, while the glutenin proteins 
can be subdivided into high molecular weight (HMW) and low molecular weight 
(LMW) subunits.  The majority of the coeliac investigations have focused on CD 
toxic gluten peptides from wheat (Tye din et al 2010, Camarca et al 2009, Dewar 
2006, Molberg et al 2003, Vader et al 2002a, Vader et al 2002b, Anderson et al 
2000, Arentz-Hansen et al 2000, and van de Wal et al 1998). Studies involving 
barley and rye are not as numerous (Tye Din et al 2010, Kilmartin et al 2006 and 
Vader et al 2003).  
 
Wheat α-gliadin-derived peptides have always been thought to be the most CD 
immunodominant. However, several studies have suggested omega-gliadin to 
contain potentially more CD toxic gluten peptides (Camarca 2009, Tye-Din 2010). 
The selected peptides in this study:  ω-gliadin/C-hordein and rye peptide (Tye 
Din 2010) are thought to contain the CD toxic epitopes (Sollid 2012). The 
nomenclature of CD relevant epitopes has been recently classsified with certain 
CD toxic motifs listed as unique epitopes because they derive from different 
cereal species (Sollid 2012). Wheat ω-gliadin/C-hordein comprises of overlapping 
nine amino acid of DQ2.5-glia-ω1 epitope (Sollid 2012) that is classified as    
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DQ2-ω-I by different author(Tye din 2010); and DQ2.5-glia-ω2 (Sollid 
2012)/DQ2-ω-II (Tye din 2010).  The rye-derived peptide lies in the sequences of 
Sec-α-2 and Sec-α-9, thought to be homologue to DQ2-α-2 and DQ2-α-1 (Vader 
2003), respectively. 
 
We have shown that ω-gliadin/C-hordein and rye peptide are CD immunogenic 
when tested with CD small intestinal gluten sensitive T cell lines.  The majority 
of wheat gluten small intestinal T cell lines cross reacted with these immunogenic 
peptides. Our study confirms the presence of other important peptides in several 
Triticae prolamins, other than wheat that could be potentially CD toxic. The 
author experienced difficulties in establishing CD sensitive T cell lines to barley 
hordein and rye secalin. However, the author has proven that T cell lines to 
barley hordein and rye secalin could be generated in addition to wheat gluten 
protein. These were achieved by co-culturing biopsies from patients with 
digested prolamins (peptic-tryptic) derived from barley hordein and rye secalin. 
This is, to our knowledge, the first demonstrations of barley and rye stimulating 
small intestinal immune responses at an initial stage. Nine barley hordein 
sensitive T cell lines and 2 rye secalin sensitive T cells were established. 
Following the success establishing T cell lines to barley and rye prolamins, we 
suggest these prolamins fractions could initiate future investigation to explore 
other potentially CD toxic barley and rye peptides. 
 
The in vitro study of barley and rye peptides (Chapter Three) has directed us with 
attempts to produce MAbs to those peptides. The second aim of the thesis is based 
on the idea that the immunogenic peptides would have the potential to elicit an 
immune response in mice. This would allow specific MAbs to be developed, 
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which in turn would serve to improve the sensitivity and specificity of 
quantifying CD toxic protein in GFD foods to individuals with CD. 
 
Several studies have generated MAbs to CD toxic wheat and rye fractions 
(Sanchez 2007, Spanej Dekking 2004, Sorell 1998, Ellis 1998, Skerritt 1985 and 
Ellis 1993).  The potential generation of MAbs to ω-gliadin/C-hordein and a rye 
derived peptide is the first attempts to our knowledge to raise such antibodies. 
Should the MAbs to these peptides be produced, they could be used in assays that 
have the potential to detect and quantify additional CD immunogenic peptides in 
wheat gluten, rye secalin and barley hordein.  
 
We have demonstrated the successful immunisation of mice. However, the 
resultant antibody of interest could not be produced. It is suggested that this 
approach could be repeated with higher doses of immunogen. In addition, the 
intervals between those immunisations should be further optimised. The ELISA 
screening of sera from immunised mice was undertaken after the second 
immunisations. The author suggests additional immunisations are required to 
immunise the mice adequately to generate MAbs. This was previously guided by 
UK Home Office regulations that reduced the number of immunisations. 
 
The final component of this PhD study was to develop improved assays for gluten 
quantification in foods (Chapter Five). Using MAbs previously generated by 
investigators within our group, the student has attempted to combine the MAbs 
as in cocktail ELISA format. The two main questions were: 1) Will these assays 
able to quantify glutenin? 2) Will a combination (Cocktail) of different MAbs 
improve the sensitivity and specificity to quantify CD toxic prolamins in 
commercially available gluten-free products for individuals with CD? 
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The answer to the first question is definitely yes since MAb raised to glutenin was 
employed. This approach is assumed to be more valid than the currently 
approved that utilised a MAb raised against rye secalin, R5 ELISA. The latter has 
already been known not to be able to quantify glutenin, that is equally or 
potentially more CD toxic than wheat gliadin. Despite the ability of the proposed 
assay to detect glutenin, the combinations of MAbs yielded lower value of gluten 
compared to gluten measurement individually with a single MAb.  
 
The knowledge of coeliac toxic epitopes, and bio-informatics could be combined 
to select other potential CD toxic peptides as a prelude to generating 
commercially available gluten-free foods. We suggest it is possible that many 
coeliac toxic peptides could be used to develop MAbs with a wide reactivity to 
CD toxic epitopes. 
 
6.2 Conclusion 
The aims of this study were to investigate the CD immunogenicity of barley an 
ω-gliadin/C-hordein peptide and a rye derived peptide, to produce MAbs to these 
peptides and to develop an ELISA in the cocktail competition format for gluten 
quantification in foods for individuals with CD.   
 
We established CD sensitive T cell lines to wheat gluten (n=14), barley hordein 
(n=9) and rye secalin (n=2). The majority of the gluten sensitive T cell lines 
demonstrated cross reactivity to ω-gliadin/C-hordein peptide and rye peptide. 
This suggests that these peptides have CD immunogenicity and potentially in 
vivo CD toxic. These peptides could also be present in all Triticeae prolamins. In 
the MAb production to the described peptides, successful murine immunisations 
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were demonstrated with various amount of immunogen that was PPD-conjugated 
peptides. The resultant antibody was rather IgM than IgG, that is relatively 
unstable thus unsuitable to be used in ELISA assays for gluten quantification. 
 
Subsequently, the development of Cocktail ELISA was assumed to be competent 
of measuring toxic proteins, gliadin and glutenin. However, the combinations of 
MAbs, previously developed by our research group appeared not to have 
improved sensitivity. The aims of the project were to be successful although they 
do not fulfil the desired targets. The results of these studies can be considered to 
be fundamental for undertaking further related work. An example method of the 
cocktail ELISA development (Chapter Five) for instance, can be used as a 
preliminary study for further future work. 
 
6.3 Future proposals 
This study has demonstrated the CD immunogenicity of ω-gliadin/C-hordein and 
rye-derived peptide in small intestinal gluten sensitive T cell line. It would be 
interesting to know if these peptides could cause morphological changes in small 
intestinal biopsies of CD patients that could be assessed with a CD duodenal 
organ culture biopsy technique. This would complement the current data. The 
attempt to develop MAbs resulted in the production of IgM rather than IgG 
antibody. It is anticipated that in the future, subsequent generation of MAb to CD 
toxic prolamins could be undertake using the same immunogens.  Increasing the 
number of immunisations is another option to generate IgG class of antibody. 
These additional procedures have been accepted by the Animal Ethics Committee 
at King’s College London and forwarded to the Home Office Animal Project 
Licence for a renewal that will permit the increased number of immunisations.  
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Should MAbs to ω-gliadin/C-hordein peptide and rye peptide be raised, they 
could be tested for cross-reactivity against the selected peptides. Other MAbs 
could be used to determine the best combination of MAbs besides those that have 
been previously suggested. This could lead to the development of improved 
cocktail competition ELISA assays with wider specificity and greater sensitivity 
to quantify CD toxic proteins and peptides in commercially gluten-free foods for 























Appendix I: Materials and Reagents 
Chapter three: Investigation of CD Immunogenicity of Barley and Rye Peptides 
1) Autologous serum medium (ASM)-for 50ml 
-500µl or 1/100 amphotericin B (0.25mg/ml, P11-001, PAA) 
-500µl or 1/100 HEPES buffer (H0887, Sigma) 
-50µl or 1/1000 plasmocin (25µg/ml, ant-mpt, Invivogen)  
-5ml or 1/10 autologous, heat inactivated serum (from coeliac patients) 
-44ml of RPMI 1640 with L-glutamine (PAA) 
 
2) Organ culture medium-for 2ml 
-25µl or 1/100 amphotericin B (0.25mg/ml, P11-001, PAA) 
-25µl or 1/100 HEPES buffer (H0887, Sigma) 
-2.5µl or 1/1000 plasmocin (25μg/ml, ant-mpt, Invivogen)  
-375µl heat-inactivated foetal calf serum (PAA) 
-2ml RPMI 1640 with L-glutamine (PAA) 
 
3) Deamidation mixture-for 500µl 
-10µl (10mg/ml) of peptic tryptic (PT) digested gluten (Roquette Ltd Corby 
Northants) or barley or rye (Plant Breeding International, Trumpington) 
- 135µl calcium chloride (2mM, P4417, Sigma) 





Chapter Four: Production of MAbs to immunogenic peptides of ω-glaidin/c-
hordein and rye secalin 















2) HAT medium-for 50ml 
-1 ml or 2% HAT (H0262, Sigma) 
-10ml or 10% heat inactivated foetal calf serum (PAA) 
-500µl or 1% Amphotericin B (PAA) 
-25µl or 0.05% Plasmocin (25μg/ml, ant-mpt, Invivogen) 




g% (w/w)  
Casein  20.00  
Choline Bitartrate  0.25  
L-Cystine  0.30  
Dextrinized Starch  13.20  
Corn Starch  39.75  
Cellulose  5.00  
Soya Oil  7.00  
Sucrose  10.00  
Mineral Mix  
829912 AIN-93G-MX  
3.50  
Vitamin Mix  








3) HT medium-for 50ml 
-1ml or 2% HT (H0137, Sigma) 
-10ml or 20% heat inactivated foetal calf serum (PAA) 
-500µl or 1% Amphotericin B (PAA) 
-25µl or 0.05% Plasmocin (25μg/ml, ant-mpt, Invivogen) 
-38.5ml RPMI 1640 with L glutamine (PAA) 
 
4) Myeloma cells medium-for 50ml 
-10ml or 20% fetal calf serum (PAA) 
-500µl or 1% Amphotericin (PAA) 
-50µl or 0.1% Plasmocin (25µg/ml, ant-mpt, Invivogen) 
-39.5ml RPMI with L-glutamine (PAA)  
 
5) Single strength antibiotic medium (50ml) 
-1000µl or 2% Penicillin/Streptomycin (5000U/ml, Gibco, Life 
Technologies) 
-250µl or 0.5% Gentamicin (10mg/ml, G1272, Sigma) 
-500µl or 1% Amphotericin B (PAA) 
-48.25ml RPMI 1640 (PAA) 
 
6) Double strength antibiotic medium (50ml) 
-2000µl or 4% Penicillin/Streptomycin (5000U/ml, Gibco, Life 
Technologies) 
-500µl or 1% Gentamicin (10mg/ml, G1272, Sigma I) 
-1000µl or 2% Amphotericin B (PAA) 




7) Complete medium-for 10ml 
-1000µl or 10% heat inactivated foetal calf serum (PAA) 
-5µl or 0.05% Plasmocin (25µg/ml, ant-mpt, Invivogen) 
-9ml RPMI with L-glutamine (PAA) 
 
8) Serum free-medium-for 10ml 
-5µl or 0.05% Plasmocin (25µg/ml, ant-mpt, Invivogen) 






















Chapter five: Development of cocktail competition ELISA for gluten 
quantification in starches 
1) TCEP buffer 
-40% (v/v) Tris-HCl solution 
-0.1% TCEP reducing agent 
-60% (v/v) glycerol 
 
2) Tris-HCl solution 
-2.422g TRIZMA Base (Sigma) 
-2.76ml of 6N HCl (Scharlau) 
-Make up with 400ml of distilled water  
 
3) Phosphate buffer saline/ PBS tween 
-5 PBS tablet (Sigma) 
- 500µl or 0.05% of Tween 20 (VWR International Ltd) 
-1 litre of distilled water 
 
4) Carbonate coating buffer (pH 9.6) 
-1 carbonate-bicarbonate buffer capsule (Sigma) 
-200ml of distilled water 
 
5) Second layer detection antibody 
-1/2000 antimouse IgG or IgM alkaline phosphatase (Sigma) 





Appendix II: Reagents and Equipment addresses of suppliers 
Amersham Biosciences UK Ltd, Amersham Place, Little Chalfont, 
Buckinghamshire HP7 9NA, UK 
 
BD Plastipak, 1 Becton Drive Franklin Lakes, NJ USA 07417 
 
Falcon, Becton Dickson Ltd, Cowley, Oxford, UK 
 
GenScript USA Inc., 860 Centennial Ave, Piscataway, NJ 08854, USA 
 
Harlan Teklad, Shaws Farm, Blackthorn, Bicester, Oxfordshire, OX25 1TP, UK 
 
Health Protection Agency Culture Collections, Centre for Emergency 
Preparedness and Response, Porton Down, Salisbury SP4 0JG, UK 
 
InvivoGen, Autogen Bioclear, Calne, Wiltshire, UK 
 
LEO Laboratories Ltd, Longwick Road, Princes Risborough, Buckinhamshire, 
HP27 9RR, UK 
 
PerkinElmer, Chalfont Road, Seer Green, Buckinghamshire HP9 2FX, UK 
 
Nunc A/S, Kamstrupvej 90, Postbox 280 DK-4000 Roskilde, Denmark 
 
PAA Laboratories, PAA-Strasse 1, 4061 Pashing, Austria 
 
PerkinElmer, Chalfont Road, Seer Green, Buckinghamshire HP9 2FX, UK 
 
Scientific Laboratory Supplies Ltd (SLS), Orchard House, The Square, Hessle, East 
Riding of Yorkshire, HU13 0AE, UK 
 
Sigma-Aldrich Company Ltd, Fancy Road, Poole, Dorset BH12 4QH, UK 
 
Statens Serum Institut (SSI), 5Artillerivej, 2300 Coperhagen S, Denmark 
VWR International-Jencons Ltd, Hunter Boulevard, Magna Park, Lutterworth, 
Leicestershire LE17 4XN, UK 
 




Plant Breeding International, Trumpington, Cambridge, UK 
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